

Primary systemic amyloidosis: clinical and laboratory f

Seminars in Hematology

32, 45-59

Citation Report

#	ARTICLE	IF	CITATIONS
1	Heart transplantation in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1995, 2, 284-287.	1.4	3
2	Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis). <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1995, 2, 269-279.	1.4	49
3	Restrictive Cardiomyopathy. <i>New England Journal of Medicine</i> , 1997, 336, 1917-1918.	13.9	3
4	A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine. <i>New England Journal of Medicine</i> , 1997, 336, 1202-1207.	13.9	656
5	Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes.. <i>Heart</i> , 1997, 78, 74-82.	1.2	164
6	BIOLOGY AND THERAPY OF IMMUNOGLOBULIN DEPOSITION DISEASES. <i>Hematology/Oncology Clinics of North America</i> , 1997, 11, 89-110.	0.9	48
7	Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. <i>American Heart Journal</i> , 1997, 134, 994-1001.	1.2	55
8	Electrophysiologic Abnormalities in AL (Primary) Amyloidosis With Cardiac Involvement. <i>Journal of the American College of Cardiology</i> , 1997, 30, 1046-1051.	1.2	135
9	Treatment of AL-Amyloidosis with Dexamethasone Plus Alpha Interferon. <i>Leukemia and Lymphoma</i> , 1997, 27, 351-356.	0.6	54
10	Kinetics of Central Nervous System Microglial and Macrophage Engraftment: Analysis Using a Transgenic Bone Marrow Transplantation Model. <i>Blood</i> , 1997, 90, 986-993.	0.6	312
11	Right Ventricular Dilation in Primary Amyloidosis. <i>American Journal of Cardiology</i> , 1997, 80, 486-492.	0.7	100
12	Features and Prognosis of Exertional Syncope in Light-Chain Associated AL Cardiac Amyloidosis. <i>American Journal of Cardiology</i> , 1997, 80, 1242-1245.	0.7	109
13	Diffuse mesenteric amyloidosis. <i>Digestive Diseases and Sciences</i> , 1997, 42, 1079-1082.	1.1	12
14	Fine-needle aspiration cytology of amyloid associated with nonneoplastic and malignant lesions. <i>Diagnostic Cytopathology</i> , 1998, 18, 270-275.	0.5	38
15	A review of the amyloidoses that infiltrate the heart. <i>Clinical Cardiology</i> , 1998, 21, 547-552.	0.7	60
16	The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. <i>British Journal of Cancer</i> , 1998, 78, 774-776.	2.9	35
17	Familial amyloid with a transthyretin leucine 33 mutation presenting with ascites. , 1998, 59, 249-251.		7
18	Amyloidosis mimicking rheumatoid arthritis. <i>Clinical Rheumatology</i> , 1998, 17, 409-411.	1.0	15

#	ARTICLE	IF	CITATIONS
19	A Glycosylated Bence Jones Protein and its Autologous Amyloid Light Chain Containing Potentially Amyloidogenic Residues. <i>Scandinavian Journal of Immunology</i> , 1998, 47, 348-354.	1.3	25
20	Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. <i>British Journal of Haematology</i> , 1998, 101, 766-769.	1.2	219
21	Cutaneous deposition diseases. Part I. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, 149-171.	0.6	195
22	Type 1 Gaucher Disease: Phenotypic Expression and Natural History in Japanese Patients. <i>Blood Cells, Molecules, and Diseases</i> , 1998, 24, 73-81.	0.6	29
23	Prognosis of Patients with Primary Systemic Amyloidosis Who Present with Dominant Neuropathy Supported in part by the Quade Amyloidosis Research Foundation and Program Project Grant No. CA 62242, National Cancer Institute (National Institutes of Health).. <i>American Journal of Medicine</i> , 1998, 104, 232-237.	0.6	135
24	The liver in systemic amyloidosis: insights from ¹²³ I serum amyloid P component scintigraphy in 484 patients. <i>Gut</i> , 1998, 42, 727-734.	6.1	110
25	Case 20-1998. <i>New England Journal of Medicine</i> , 1998, 338, 1905-1913.	13.9	6
26	Pathophysiology of paraprotein production. <i>Renal Failure</i> , 1998, 20, 821-828.	0.8	21
27	Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. <i>Blood</i> , 1998, 91, 3662-3670.	0.6	323
28	Long-Term Survival (10 Years or More) in 30 Patients With Primary Amyloidosis. <i>Blood</i> , 1999, 93, 1062-1066.	0.6	180
29	Treatment of AL Amyloidosis with 4-iodo-4-deoxydoxorubicin: An Update. <i>Blood</i> , 1999, 93, 1112-1113.	0.6	41
30	Monoclonality of infiltrating plasma cells in primary pulmonary nodular amyloidosis: detection with polymerase chain reaction. <i>Journal of Clinical Pathology</i> , 1999, 52, 464-467.	1.0	26
31	Amyloidosis and the respiratory tract. <i>Thorax</i> , 1999, 54, 444-451.	2.7	188
32	Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. <i>British Journal of Haematology</i> , 1999, 104, 553-559.	1.2	68
33	Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. <i>British Journal of Haematology</i> , 1999, 106, 744-751.	1.2	79
34	pH-dependent fibrillogenesis of a Λ III Bence Jones protein. <i>British Journal of Haematology</i> , 1999, 107, 835-843.	1.2	31
35	Paraneoplastic glomerulopathies: New insights into an old entity. <i>Kidney International</i> , 1999, 56, 355-377.	2.6	199
37	Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1999, 16, 104-109.	1.0	47

#	ARTICLE	IF	CITATIONS
38	Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. , 1999, 61, 115-119.		40
39	Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1999, 6, 273-277.	1.4	18
40	Monoclonal gammopathies and associated skin disorders. <i>Journal of the American Academy of Dermatology</i> , 1999, 40, 507-535.	0.6	202
41	AMYLOIDOSIS. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 1211-1233.	0.9	141
42	NONAMYLOIDOTIC MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 1235-1248.	0.9	150
43	Amyloidosis: Recognition, Confirmation, Prognosis, and Therapy. <i>Mayo Clinic Proceedings</i> , 1999, 74, 490-494.	1.4	49
44	Amyloidosis: Recognition, Confirmation, Prognosis, and Therapy. <i>Mayo Clinic Proceedings</i> , 1999, 74, 490-494.	1.4	108
45	Hemorrhagic lymphadenopathy as a presenting feature of primary al amyloidosis. <i>Pathology</i> , 2000, 32, 21-23.	0.3	7
46	Infiltrative Nonamyloidotic Monoclonal Immunoglobulin Light Chain Cardiomyopathy: An Underappreciated Manifestation of Plasma Cell Dyscrasias. <i>Cardiology</i> , 2000, 93, 220-228.	0.6	44
47	Therapeutic apheresis in neurological disorders. <i>Journal of Clinical Apheresis</i> , 2000, 15, 74-128.	0.7	66
48	Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). <i>Bone Marrow Transplantation</i> , 2000, 26, 963-969.	1.3	88
49	Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. <i>Bone Marrow Transplantation</i> , 2000, 25, 465-470.	1.3	72
50	Liver transplantation as rescue treatment in a patient with primary AL kappa amyloidosis. <i>Transplant International</i> , 2000, 13, 92-97.	0.8	33
51	Five or more years of survival in patients with primary systemic amyloidosis and biopsy-proven cardiac involvement. <i>American Journal of Cardiology</i> , 2000, 85, 664-665.	0.7	25
52	Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal pain and their relation to histopathologic findings. <i>American Journal of Cardiology</i> , 2000, 85, 849-853.	0.7	38
53	Hematopoietic Cell Transplantation for Primary Systemic Amyloidosis: What Have We Learned. <i>Leukemia and Lymphoma</i> , 2000, 37, 245-258.	0.6	33
54	Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy. <i>New England Journal of Medicine</i> , 2000, 342, 1077-1084.	13.9	1,464
55	The role of high-dose chemotherapy in the treatment of multiple myeloma: A controversy. <i>Annals of Oncology</i> , 2000, 11, S55-S58.	0.6	11

#	ARTICLE	IF	CITATIONS
56	FISH Demonstrates Treatment-Related Chromosome Damage in Myeloid but not Plasma Cells in Primary Systemic Amyloidosis. <i>Leukemia and Lymphoma</i> , 2000, 39, 391-395.	0.6	11
57	Antibody-Mediated Resolution of Light Chain-Associated Amyloid Deposits. <i>American Journal of Pathology</i> , 2000, 157, 1239-1246.	1.9	188
58	Novel approaches to the treatment of primary amyloidosis. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 2343-2350.	1.9	13
59	AL amyloidosis: The last 30 years. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2000, 7, 13-14.	1.4	13
60	Primary Localized Amyloidosis of the Urinary Bladder: A Case Series of 31 Patients. <i>Mayo Clinic Proceedings</i> , 2000, 75, 1264-1268.	1.4	119
62	Hepatic amyloidosis with light chain deposition disease. A rare association. <i>Digestive and Liver Disease</i> , 2000, 32, 795-798.	0.4	17
63	CIRCULATORY SHOCK. <i>Critical Care Clinics</i> , 2001, 17, 697-719.	1.0	11
64	Vertebral amyloidoma in a patient with primary systemic amyloidosis. <i>American Journal of Medicine</i> , 2001, 110, 594-596.	0.6	2
65	Primary systemic amyloidosis: a cause of malabsorption syndrome. <i>American Journal of Medicine</i> , 2001, 111, 535-540.	0.6	65
66	Subcutaneous nodular amyloidosis: A case report and review of the literature. <i>Human Pathology</i> , 2001, 32, 346-348.	1.1	19
67	An unusual cause of bleeding. <i>Lancet, The</i> , 2001, 358, 1424.	6.3	4
68	Current Role of Endomyocardial Biopsy in the Management of Dilated Cardiomyopathy and Myocarditis. <i>Mayo Clinic Proceedings</i> , 2001, 76, 1030-1038.	1.4	91
69	Amyloidotic muscle pseudohypertrophy: case report. <i>Arquivos De Neuro-Psiquiatria</i> , 2001, 59, 582-586.	0.3	6
70	The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden. <i>Blood</i> , 2001, 98, 714-720.	0.6	251
71	Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. <i>Blood</i> , 2001, 98, 2266-2268.	0.6	135
72	A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. <i>British Journal of Haematology</i> , 2001, 113, 1044-1046.	1.2	67
73	Shoulder-Pad Sign of Amyloidosis: Structure of an Ig Kappa III Protein. <i>Scandinavian Journal of Immunology</i> , 2001, 54, 404-408.	1.3	15
74	Amyloidosis of the tongue with kappa light chain disease. <i>Australasian Journal of Dermatology</i> , 2001, 42, 55-57.	0.4	10

#	ARTICLE	IF	CITATIONS
75	Four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001, 27, 341-343.	1.3	10
76	High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. <i>Bone Marrow Transplantation</i> , 2001, 28, 381-385.	1.3	42
77	An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. <i>Bone Marrow Transplantation</i> , 2001, 28, 637-642.	1.3	149
78	Biological features of the clone involved in primary amyloidosis (AL). <i>Leukemia</i> , 2001, 15, 195-202.	3.3	18
79	Amyloidosis. <i>Postgraduate Medical Journal</i> , 2001, 77, 686-693.	0.9	61
80	Chemical Typing of Amyloid Protein Contained in Formalin-Fixed Paraffin-Embedded Biopsy Specimens. <i>American Journal of Clinical Pathology</i> , 2001, 116, 135-142.	0.4	145
81	Counteracting Effects of Renal Solutes on Amyloid Fibril Formation by Immunoglobulin Light Chains. <i>Journal of Biological Chemistry</i> , 2001, 276, 1626-1633.	1.6	81
82	Long term results of heart transplantation in patients with amyloid heart disease. <i>British Heart Journal</i> , 2001, 85, 202-207.	2.2	91
83	Cardiac Amyloidosis Presenting as Microvascular Angina. <i>Angiology</i> , 2001, 52, 273-278.	0.8	27
84	Case 9-2001. <i>New England Journal of Medicine</i> , 2001, 344, 917-923.	13.9	9
85	The Antisense Approach in Amyloid Light Chain Amyloidosis: Identification of Monoclonal Ig and Inhibition of Its Production by Antisense Oligonucleotides in In Vitro and In Vivo Models. <i>Journal of Immunology</i> , 2002, 169, 4039-4045.	0.4	21
86	Amyloid a Protein Amyloidosis in a Patient with Plasma Cell Dyscrasia.. <i>Internal Medicine</i> , 2002, 41, 386-391.	0.3	3
87	AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2002, 9, 165-174.	1.4	51
88	Autologous stem cell transplantation for primary systemic amyloidosis. <i>Blood</i> , 2002, 99, 4276-4282.	0.6	335
89	Stem cell transplantation for the management of primary systemic amyloidosis. <i>American Journal of Medicine</i> , 2002, 113, 549-555.	0.6	157
90	Analysis of λ expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies $3r(\lambda)$ as a new amyloid-associated germline gene segment. <i>Blood</i> , 2002, 100, 948-953.	0.6	147
92	Primary Amyloidosis Presenting with Massive Generalized Lymphadenopathy. <i>Leukemia and Lymphoma</i> , 2002, 43, 1501-1503.	0.6	10
93	Non-Cancerous Ophthalmic Clues to Non-Ocular Cancer. <i>Survey of Ophthalmology</i> , 2002, 47, 397-430.	1.7	4

#	ARTICLE	IF	CITATIONS
94	Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. <i>American Heart Journal</i> , 2002, 144, 122-129.	1.2	58
95	Progressive generalized alopecia due to systemic amyloidosis. <i>Journal of the American Academy of Dermatology</i> , 2002, 46, 434-436.	0.6	22
97	Utility of Subcutaneous Fat Aspiration for Diagnosing Amyloidosis in Patients With Isolated Peripheral Neuropathy. <i>Mayo Clinic Proceedings</i> , 2002, 77, 1287-1290.	1.4	33
98	Diagnosing Primary Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2002, 77, 1278-1279.	1.4	15
99	Serum Reference Intervals and Diagnostic Ranges for Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains. <i>Clinical Chemistry</i> , 2002, 48, 1437-1444.	1.5	577
100	A rare complication of monoclonal gammopathy. <i>American Journal of Kidney Diseases</i> , 2002, 40, 867-871.	2.1	8
101	Diagnostic tools for amyloidosis. <i>Joint Bone Spine</i> , 2002, 69, 538-545.	0.8	63
102	Primary systemic amyloidosis. <i>Current Treatment Options in Oncology</i> , 2002, 3, 261-271.	1.3	48
103	Establishment of a first-order kinetic model of light chain-associated amyloid fibril extension in vitro. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2002, 1601, 110-120.	1.1	24
104	Moyens paracliniques du diagnostic des amyloses. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2002, 69, 1172-1180.	0.0	5
105	Immunoglobulin light chain amyloidosis and the kidney. <i>Kidney International</i> , 2002, 61, 1-9.	2.6	94
106	Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. <i>British Journal of Haematology</i> , 2002, 117, 427-435.	1.2	65
107	Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. <i>British Journal of Haematology</i> , 2002, 117, 886-889.	1.2	46
108	Cutaneous amyloidosis and possible association with systemic amyloidosis. <i>International Journal of Dermatology</i> , 2002, 41, 127-132.	0.5	58
109	Cutaneous and systemic amyloidoses. <i>International Journal of Dermatology</i> , 2002, 41, 133-134.	0.5	10
110	Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis. <i>Bone Marrow Transplantation</i> , 2002, 30, 279-285.	1.3	8
111	Etanercept Therapy in Patients with Advanced Primary Amyloidosis. <i>Medical Oncology</i> , 2003, 20, 283-290.	1.2	19
112	Gastrointestinal amyloidosis: Approach to treatment. <i>Current Treatment Options in Gastroenterology</i> , 2003, 6, 17-25.	0.3	16

#	ARTICLE	IF	CITATIONS
113	Atypical presentations of primary amyloid neuropathy. <i>Muscle and Nerve</i> , 2003, 28, 696-702.	1.0	30
114	Spontaneous rupture of the spleen in AL amyloidosis. <i>American Journal of Hematology</i> , 2003, 74, 131-135.	2.0	56
115	Biclonal Systemic AL-Amyloidosis with One Glycosylated and One Nonglycosylated AL-Protein*. <i>Scandinavian Journal of Immunology</i> , 2003, 57, 319-323.	1.3	11
116	High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. <i>Kidney International</i> , 2003, 63, 1051-1057.	2.6	59
117	Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. <i>British Journal of Haematology</i> , 2003, 122, 78-84.	1.2	370
118	NeuropatÃas hereditarias. <i>Medicine</i> , 2003, 8, 5379-5385.	0.0	0
119	Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. <i>Lancet</i> , The, 2003, 361, 1787-1789.	6.3	277
121	The spectrum of cutaneous disease in multiple myeloma. <i>Journal of the American Academy of Dermatology</i> , 2003, 48, 497-507.	0.6	90
122	Amyloid deposition in the oral cavity: A retrospective study and review of the literature. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2003, 95, 674-680.	1.6	43
123	Quantitative Analysis of Serum Free Light Chains. <i>American Journal of Clinical Pathology</i> , 2003, 119, 274-278.	0.4	176
124	Localized AL amyloidosis of the colon: an unrecognized entity. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2003, 10, 36-41.	1.4	25
125	Evaluation of intensive chemotherapy in AL amyloidosis: usefulness of flow cytometric analysis of plasma cells in bone marrow. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2003, 10, 250-256.	1.4	6
126	Quantitative Analysis of Serum Free Light Chains: A New Marker for the Diagnostic Evaluation of Primary Systemic Amyloidosis. <i>American Journal of Clinical Pathology</i> , 2003, 119, 274-278.	0.4	54
127	Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2003, 10, 110-116.	1.4	26
128	Localized epidural and bone amyloidosis, rare cause of paraplegia in multiple myeloma. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2003, 10, 47-50.	1.4	12
129	Bone marrow immunohistology of plasma cell neoplasms. <i>Journal of Clinical Pathology</i> , 2003, 56, 406-411.	1.0	38
130	Persistent Pleural Effusions in Primary Systemic Amyloidosis. <i>Chest</i> , 2003, 124, 969-977.	0.4	106
131	Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). <i>Blood</i> , 2003, 101, 3801-3807.	0.6	207

#	ARTICLE	IF	CITATIONS
132	Expression of CD52 on plasma cells in plasma cell proliferative disorders. <i>Blood</i> , 2003, 102, 1075-1077.	0.6	48
133	Nephrotic Syndrome Due to Primary AL Amyloidosis, Successfully Treated with VAD and Subsequent High-dose Melphalan Followed by Autologous Peripheral Blood Stem Cell Transplantation.. <i>Internal Medicine</i> , 2003, 42, 72-77.	0.3	20
134	Primary Amyloidosis with Pulmonary Involvement which Presented Exudative Pleural Effusion and High Fever. <i>Internal Medicine</i> , 2003, 42, 756-760.	0.3	12
135	Domino Liver Transplantation: A Practical Option in the Face of the Organ Shortage. <i>Progress in Transplantation</i> , 2003, 13, 151-153.	0.4	5
136	Anasarca secondary to problems in three organs: one man with three diseases?. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1651-1653.	0.4	0
137	A rare transthyretin mutation (Asp18Glu) associated with cardiomyopathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2004, 11, 61-66.	1.4	14
138	IgM AL amyloidosis due to B cell lymphoproliferative disorder: efficacy of high-dose melphalan followed by autologous stem cell transplantation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2004, 11, 130-135.	1.4	8
139	Systemic amyloidosis manifesting as localized, severe periodontitis. <i>Journal of the American Dental Association</i> , 2004, 135, 617-623.	0.7	9
140	Guidelines on the diagnosis and management of AL amyloidosis. <i>British Journal of Haematology</i> , 2004, 125, 681-700.	1.2	106
141	Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. <i>Bone Marrow Transplantation</i> , 2004, 33, 271-277.	1.3	61
142	High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. <i>Bone Marrow Transplantation</i> , 2004, 33, 381-388.	1.3	107
143	Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion. <i>European Journal of Haematology</i> , 2004, 72, 181-185.	1.1	8
144	Long-term outcome of renal transplantation in light-chain deposition disease. <i>American Journal of Kidney Diseases</i> , 2004, 43, 147-153.	2.1	187
145	Successful perioperative management of factor X deficiency associated with primary amyloidosis. <i>Journal of Gastrointestinal Surgery</i> , 2004, 8, 358-362.	0.9	32
146	Therapy for immunoglobulin light chain amyloidosis: the new and the old. <i>Blood Reviews</i> , 2004, 18, 17-37.	2.8	59
147	The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. <i>Journal of Internal Medicine</i> , 2004, 255, 159-178.	2.7	198
148	Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. <i>British Journal of Haematology</i> , 2004, 124, 309-314.	1.2	58
149	VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2004, 11, 245-256.	1.4	37

#	ARTICLE	IF	CITATIONS
150	Primary AL-amyloidosis, ulcerative colitis and collagenous colitis in a 57-year-old woman: a case study. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 1306-1309.	0.6	15
152	Nefropatías glomerulares. Orientación diagnóstica y evolución. <i>EMC - Tratado De Medicina</i> , 2004, 8, 1-7.	0.0	0
154	Eyelid bleeding and atypical amyloidosis. <i>American Journal of Ophthalmology</i> , 2004, 138, 495-496.	1.7	17
155	Cardiac transplantation for amyloid heart disease: The United Kingdom experience. <i>Journal of Heart and Lung Transplantation</i> , 2004, 23, 1142-1153.	0.3	165
157	Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. <i>Blood</i> , 2004, 104, 1881-1887.	0.6	300
158	Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. <i>Blood</i> , 2004, 103, 3960-3963.	0.6	226
159	Recurrent Gastric Hemorrhaging with Large Submucosal Hematomas in a Patient with Primary AL Systemic Amyloidosis: Endoscopic and Histopathological Findings. <i>Internal Medicine</i> , 2004, 43, 468-472.	0.3	21
160	Cardiac Amyloidosis: Heterogenous Pathogenic Backgrounds. <i>Internal Medicine</i> , 2004, 43, 1107-1114.	0.3	26
161	Pleural effusions in systemic amyloidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2005, 11, 324-328.	1.2	39
162	Serum Levels of Free Light Chain before and after Chemotherapy in Primary Systemic AL Amyloidosis. <i>Internal Medicine</i> , 2005, 44, 428-433.	0.3	24
163	High-dose Melphalan Followed by Autologous Stem Cell Support in Primary Systemic AL Amyloidosis with Multiple Organ Involvement. <i>Internal Medicine</i> , 2005, 44, 484-489.	0.3	6
164	Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. <i>Blood</i> , 2005, 105, 794-803.	0.6	52
165	Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. <i>Blood</i> , 2005, 106, 3353-3357.	0.6	44
166	Peripheral blood progenitor cell mobilization and collection in 42 patients with primary systemic amyloidosis. <i>Transfusion</i> , 2005, 45, 1729-1734.	0.8	15
167	Emerging treatment approaches for the systemic amyloidoses. <i>Kidney International</i> , 2005, 68, 1377-1390.	2.6	34
168	Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. <i>Bone Marrow Transplantation</i> , 2005, 35, 567-575.	1.3	33
169	Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. <i>American Journal of Cardiology</i> , 2005, 95, 535-537.	0.7	263
170	Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. <i>American Journal of Kidney Diseases</i> , 2005, 45, 102-111.	2.1	34

#	ARTICLE	IF	CITATIONS
171	Renal Response After High-Dose Melphalan and Stem Cell Transplantation Is a Favorable Marker in Patients With Primary Systemic Amyloidosis. <i>American Journal of Kidney Diseases</i> , 2005, 46, 270-277.	2.1	74
172	Autologous Stem Cell and Kidney Transplantation for Primary Amyloidosis Associated with ESRD: Which Should Come First?. <i>American Journal of Transplantation</i> , 2005, 5, 1585-1586.	2.6	7
173	Splenic hypoperfusion as a sign of systemic amyloidosis. <i>Abdominal Imaging</i> , 2005, 30, 768-772.	2.0	8
174	Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. <i>Annals of Hematology</i> , 2005, 84, 588-593.	0.8	30
175	Sudden death in nondilated cardiomyopathies: Pathophysiology and prevention. <i>Current Heart Failure Reports</i> , 2005, 2, 118-123.	1.3	7
176	Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2005, 12, 120-126.	1.4	48
177	Incidence and risk factors of venous thromboembolism (VTE) in patients with amyloidosis. <i>International Seminars in Surgical Oncology</i> , 2005, 2, 17.	1.1	14
178	Amyloid in the cardiovascular system: a review. <i>Journal of Clinical Pathology</i> , 2005, 58, 125-133.	1.0	94
179	Diaphragm paralysis in primary systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2005, 12, 193-196.	1.4	9
180	Diagnosis and Management of the Cardiac Amyloidoses. <i>Circulation</i> , 2005, 112, 2047-2060.	1.6	696
181	Cellular Response of Cardiac Fibroblasts to Amyloidogenic Light Chains. <i>American Journal of Pathology</i> , 2005, 166, 197-208.	1.9	51
182	Amylose h�patique. <i>EMC - Hepato-Gastroenterologie</i> , 2005, 2, 330-338.	0.1	0
183	BNP as A Biomarker in Heart Disease. <i>Advances in Clinical Chemistry</i> , 2005, 40, 1-36.	1.8	57
185	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Journal of the American College of Cardiology</i> , 2006, 48, e247-e346.	1.2	1,280
186	Isolated Left Atrial Amyloidosis: Acute Premitral Stenosis Secondary to Spontaneous Intramural Left Atrial Hemorrhagic Dissection. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 938.e1-938.e4.	1.2	10
187	Pathogenicity of catalytic antibodies: catalytic activity of Bence Jones proteins from myeloma patients with renal impairment can elicit cytotoxic effects. <i>Biological Chemistry</i> , 2006, 387, 543-548.	1.2	11
188	Amyloidosis and the lung. <i>Chronic Respiratory Disease</i> , 2006, 3, 203-214.	1.0	58
189	Diagnostic Performance of 123I-Labeled Serum Amyloid P Component Scintigraphy in Patients with Amyloidosis. <i>American Journal of Medicine</i> , 2006, 119, 355.e15-355.e24.	0.6	129

#	ARTICLE	IF	CITATIONS
190	Classification of amyloidosis: misdiagnosing by way of incomplete immunohistochemistry and how to prevent it. <i>Acta Histochemica</i> , 2006, 108, 197-208.	0.9	85
191	Primary cardiac amyloidosis with 20-year survival. <i>Cardiovascular Pathology</i> , 2006, 15, 331-335.	0.7	6
192	Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. <i>European Journal of Cancer</i> , 2006, 42, 1671-1683.	1.3	60
193	Plasma cell tumors with calcified amyloid mimicking chondrosarcoma. <i>European Journal of Radiology Extra</i> , 2006, 59, 131-132.	0.1	0
194	Bullous amyloidosis of the oral cavity: A rare clinical presentation and review. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2006, 101, 734-740.	1.6	36
195	Refractory hematuria from amyloidosis successfully treated by splenectomy. <i>Urology</i> , 2006, 67, 1085.e13-1085.e15.	0.5	6
196	Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 350-354.	2.2	53
197	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. <i>Blood</i> , 2006, 107, 3378-3383.	0.6	230
198	Dangerous small B-cell clones. <i>Blood</i> , 2006, 108, 2520-2530.	0.6	398
201	Primary systemic amyloidosis. <i>Postgraduate Medicine</i> , 2006, 119, 93-99.	0.9	7
202	Immunoglobulin Lightchain (AL) Amyloidosis with Myasthenic Symptoms and Echocardiographic Features of Dilated Cardiomyopathy. <i>Internal Medicine</i> , 2006, 45, 159-162.	0.3	5
203	Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. <i>British Journal of Haematology</i> , 2006, 134, 417-425.	1.2	84
204	Mucocutaneous paraneoplastic syndromes in hematologic malignancies. <i>International Journal of Dermatology</i> , 2006, 45, 14-22.	0.5	22
205	Amyloidosis. <i>Current Treatment Options in Oncology</i> , 2006, 7, 225-236.	1.3	32
206	Cardiac amyloidosis: Shifting our impressions to hopeful. <i>Current Heart Failure Reports</i> , 2006, 3, 64-71.	1.3	10
207	Quantitative analysis of clonal bone marrow CD19+ B cells: Use of B cell lineage trees to delineate their role in the pathogenesis of light chain amyloidosis. <i>Clinical Immunology</i> , 2006, 120, 106-120.	1.4	13
208	Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. <i>Arthritis and Rheumatism</i> , 2006, 54, 2015-2021.	6.7	193
209	Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis. <i>American Journal of Hematology</i> , 2006, 81, 281-283.	2.0	9

#	ARTICLE	IF	CITATIONS
210	Myeloma – new approaches to combined nephrological haematological management. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 582-590.	0.4	31
211	Drug Insight: emerging therapies for amyloidosis. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 263-270.	2.0	33
212	Primary (AL) Amyloidosis in Plasma Cell Disorders. <i>Oncologist</i> , 2006, 11, 824-830.	1.9	28
213	Light-Chain (AL) Amyloidosis: Diagnosis and Treatment. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 1331-1341.	2.2	191
214	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Circulation</i> , 2006, 114, e385-484.	1.6	1,031
215	Autologous stem cell transplantation and IgM amyloidosis. <i>Leukemia and Lymphoma</i> , 2006, 47, 1006-1012.	0.6	19
216	Amyloidosis-Associated Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 3458-3471.	3.0	332
217	Natural history of thromboembolism in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2006, 13, 31-36.	1.4	28
218	Congo Red Staining of Amyloid: Improvements and Practical Guide for a More Precise Diagnosis of Amyloid and the Different Amyloidoses. , 2006, , 239-276.		30
219	A novel type of familial transthyretin amyloidosis, ATTR Asn124Ser, with co-localization of Î² light chains. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2007, 14, 141-145.	1.4	9
220	Lambda II immunoglobulin light chain protein in primary localized rectal amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2007, 14, 299-304.	1.4	4
221	Chapter 21 Amyloidosis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2007, 7, 383-396.	0.1	1
222	Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. <i>European Journal of Heart Failure</i> , 2007, 9, 808-813.	2.9	61
223	Intra-tubular amyloidosis. <i>Kidney International</i> , 2007, 72, 1282-1288.	2.6	23
224	Bleeding and Thrombosis Risks in Plasma Cell Dyscrasias. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 158-164.	0.9	46
225	Severity of Baseline Proteinuria Predicts Renal Response in Immunoglobulin Light Chain Associated Amyloidosis after Autologous Stem Cell Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 440-444.	2.2	38
226	Improvement of Cardiac Diastolic Function and Prognosis After Autologous Peripheral Blood Stem Cell Transplantation in AL Cardiac Amyloidosis. <i>Internal Medicine</i> , 2007, 46, 1705-1710.	0.3	9
227	Cardiac Transplantation Using Extended-Donor Criteria Organs for Systemic Amyloidosis Complicated by Heart Failure. <i>Transplantation</i> , 2007, 83, 539-545.	0.5	73

#	ARTICLE	IF	CITATIONS
230	An Unusual Cause of Lymph Nodes Enlargement. <i>American Journal of Medicine</i> , 2007, 120, e1-e3.	0.6	2
231	An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2007, 14, 261-269.	1.4	29
232	Clinical Recognition of AL Type Amyloidosis of the Luminal Gastrointestinal Tract. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 582-588.	2.4	64
234	Disease-associated prion protein is not detectable in human systemic amyloid deposits. <i>Journal of Pathology</i> , 2007, 213, 376-383.	2.1	5
235	Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients. <i>Histopathology</i> , 2007, 50, 567-573.	1.6	27
236	A "muscle" man without exercise: muscle pseudohypertrophy in myeloma-associated generalized amyloidosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 986-988.	1.3	6
237	Immunohistochemical and immunochemical study of amyloid in liver affected by systemic A? amyloidosis with antibodies against three different regions of immunoglobulin ? light chain. <i>Pathology International</i> , 2007, 57, 343-350.	0.6	11
238	Periarthritis nodosa and AL amyloidosis: A case report. <i>Joint Bone Spine</i> , 2007, 74, 205-206.	0.8	0
239	Novel Analysis of Clonal Diversification in Blood B Cell and Bone Marrow Plasma Cell Clones in Immunoglobulin Light Chain Amyloidosis. <i>Journal of Clinical Immunology</i> , 2007, 27, 69-87.	2.0	18
240	Deposition-associated diseases related with a monoclonal compound. <i>Clinical and Translational Oncology</i> , 2007, 9, 777-783.	1.2	1
241	An Unusual Case of Cardiac Amyloidosis. <i>Journal of General Internal Medicine</i> , 2007, 22, 1047-1052.	1.3	6
242	P?riart?rite nouvelle et? amylose AL. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 305-306.	0.0	0
244	Intraventricular dyssynchrony in light chain amyloidosis: a new mechanism of systolic dysfunction assessed by 3-dimensional echocardiography. <i>Cardiovascular Ultrasound</i> , 2008, 6, 40.	0.5	23
245	Review of peripheral neuropathy in plasma cell disorders. <i>Hematological Oncology</i> , 2008, 26, 55-65.	0.8	63
246	Perspectives in treatment of AL amyloidosis. <i>British Journal of Haematology</i> , 2008, 140, 365-377.	1.2	85
247	The evolving use of serum free light chain assays in haematology. <i>British Journal of Haematology</i> , 2008, 141, 413-422.	1.2	86
248	Bleeding Complications After Transcutaneous Kidney Biopsy in Patients With Systemic Amyloidosis: Single-Center Experience in 101 Patients. <i>American Journal of Kidney Diseases</i> , 2008, 52, 1079-1083.	2.1	70
250	Autologous Stem Cell Transplant after Heart Transplant for Light Chain (AL) Amyloid Cardiomyopathy. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 823-829.	0.3	117

#	ARTICLE	IF	CITATIONS
251	Colloid milium of the oral cavity: a rare presentation. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2008, 105, e34-e38.	1.6	7
252	Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 6-11.	2.0	22
253	Patterns of Neuropathy and Autonomic Failure in Patients With Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1226-1230.	1.4	100
254	Serum Uric Acid: Novel Prognostic Factor in Primary Systemic Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2008, 83, 297-303.	1.4	39
255	AL amyloidosis manifesting as systemic lymphadenopathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2008, 15, 117-124.	1.4	17
256	Severe intrahepatic cholestasis, erythrocytosis and hypoglycemia: Unusual presenting features of systemic AL amyloidosis. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 375-379.	0.6	10
257	Primary Restrictive, Infiltrative, and Storage Cardiomyopathies. , 2008, , 259-276.		1
258	Early cardiac involvement in senile systemic amyloidosis: a case report. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2008, 15, 54-59.	1.4	15
259	Altered Dimer Interface Decreases Stability in an Amyloidogenic Protein. <i>Journal of Biological Chemistry</i> , 2008, 283, 15853-15860.	1.6	103
260	Structural Insights into the Role of Mutations in Amyloidogenesis. <i>Journal of Biological Chemistry</i> , 2008, 283, 30950-30956.	1.6	66
261	Immunodiagnostic Capabilities of Anti- κ Free Immunoglobulin Light Chain Monoclonal Antibodies. <i>American Journal of Clinical Pathology</i> , 2008, 130, 702-711.	0.4	28
262	Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, 414-416.	1.4	2
263	Principles of Protein Misfolding. <i>Progress in Molecular Biology and Translational Science</i> , 2008, 84, 115-160.	0.9	3
264	Systemic AL Amyloidosis Mimicking Rheumatoid Arthritis. <i>Internal Medicine</i> , 2008, 47, 1133-1138.	0.3	25
265	Long-term Follow-up of Plasma Cells in Bone Marrow and Serum Free Light Chains in Primary Systemic AL Amyloidosis. <i>Internal Medicine</i> , 2008, 47, 1783-1790.	0.3	11
266	AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. <i>Blood</i> , 2008, 112, 4009-4016.	0.6	73
267	Nephrotic Syndrome Due to Primary Systemic AL Amyloidosis, Successfully Treated with VAD (Vincristine, Doxorubicin and Dexamethasone) Alone. <i>Internal Medicine</i> , 2008, 47, 543-549.	0.3	5
268	Therapeutic Outcome of Cyclic VAD (Vincristine, Doxorubicin and Dexamethasone) Therapy in Primary Systemic AL Amyloidosis Patients. <i>Internal Medicine</i> , 2008, 47, 1517-1522.	0.3	8

#	ARTICLE	IF	CITATIONS
269	The Association of Hashimoto Disease and Congo Red Negative Amyloidosis. <i>American Journal of the Medical Sciences</i> , 2008, 336, 293-296.	0.4	10
270	Scleroderma-Like Illness as a Presenting Feature of Multiple Myeloma and Amyloidosis. <i>Journal of Clinical Rheumatology</i> , 2008, 14, 161-165.	0.5	17
271	Monoclonal gammopathies. , 2008, , 1167-1180.		1
272	Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. <i>Haematologica</i> , 2009, 94, 1029-1032.	1.7	25
273	A father and his son with systemic AL amyloidosis. <i>Haematologica</i> , 2009, 94, 437-439.	1.7	19
274	Familial (ATTR) amyloidosis misdiagnosed as the primary (AL) variant: a case report. <i>Cases Journal</i> , 2009, 2, 9295.	0.4	2
275	Amyloid and the GI tract. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 615-630.	1.4	17
276	Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 63-70.	1.4	50
277	Subepithelial Pelvic Hematoma (Antopolâ€™Goldman Lesion) Simulating Renal Neoplasm: Report of a Case and Review of the Literature. <i>International Journal of Surgical Pathology</i> , 2009, 17, 264-267.	0.4	21
278	Renal involvement in AL amyloidosis: the facts, the promise and the hope. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2967-2969.	0.4	3
279	Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: A case report with literature review. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 103-107.	1.4	16
280	Rational Management of Macroglossia Due to Acquired Systemic Amyloidosis: Does Surgery Play a Role?. <i>Journal of Oral and Maxillofacial Surgery</i> , 2009, 67, 2013-2017.	0.5	14
281	Cardiac amyloidosis in a patient with multiple myeloma: A case report and review of literature. <i>Journal of Clinical Ultrasound</i> , 2009, 37, 179-184.	0.4	25
282	A case of immunotactoid glomerulopathy exhibiting nephrotic syndrome successfully treated with corticosteroids and antihypertensive therapy. <i>Clinical and Experimental Nephrology</i> , 2009, 13, 378-384.	0.7	7
283	Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation. <i>Clinical and Experimental Nephrology</i> , 2009, 13, 522-525.	0.7	10
284	Backbone and side-chain 1H, 13C and 15N resonance assignments of LEN, a human immunoglobulin Î²IV light-chain variable domain. <i>Biomolecular NMR Assignments</i> , 2009, 3, 255-259.	0.4	3
285	Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor. <i>Annals of Hematology</i> , 2009, 88, 59-66.	0.8	44
287	Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up. <i>BMC Medical Physics</i> , 2009, 9, 5.	2.4	46

#	ARTICLE	IF	CITATIONS
288	Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. <i>British Journal of Haematology</i> , 2009, 145, 151-163.	1.2	93
289	Systemic amyloidosis and the gastrointestinal tract. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 608-617.	8.2	102
290	Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 232-238.	1.4	59
291	Amyloid arthropathy mimicking seronegative rheumatoid arthritis in multiple myeloma: case reports and review of the literature. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 226-231.	1.4	17
293	Urinary Findings in Renal Light Chain-Derived Amyloidosis and Light Chain Deposition Disease. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 234-238.	1.4	4
294	Multiple Bony Amyloidomas as an Initial Presentation of Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, E18-E20.	1.4	1
295	Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 243-245.	1.4	2
296	Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 183-185.	1.4	1
297	Primary (AL) amyloidosis with gastrointestinal involvement. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 708-711.	0.6	34
298	Amiloidosis. <i>Medicine</i> , 2009, 10, 2185-2191.	0.0	0
299	Left Ventricular Ejection Time on Echocardiography Predicts Long-Term Mortality in Light Chain Amyloidosis. <i>Journal of the American Society of Echocardiography</i> , 2009, 22, 1396-1402.	1.2	39
300	Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. <i>Haematologica</i> , 2009, 94, 1094-1100.	1.7	32
301	Splenic plasma cells can serve as a source of amyloidogenic light chains. <i>Blood</i> , 2009, 113, 1501-1503.	0.6	8
302	Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. <i>Blood</i> , 2009, 114, 1489-1497.	0.6	153
303	Liver AL amyloidosis as a possible cause of high liver stiffness values. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 895-897.	0.8	32
304	Cardiac Transplantation Followed by Dose-Intensive Melphalan and Autologous Stem-Cell Transplantation for Light Chain Amyloidosis and Heart Failure. <i>Transplantation</i> , 2010, 90, 905-911.	0.5	103
306	Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 287-294.	0.9	85
307	Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. <i>Blood</i> , 2010, 116, 2241-2244.	0.6	76

#	ARTICLE	IF	CITATIONS
308	Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. <i>Blood</i> , 2010, 116, 5126-5129.	0.6	146
309	A Case of AL Amyloidosis with Renal Rupture. <i>Internal Medicine</i> , 2010, 49, 2129-2132.	0.3	0
310	Chylous Ascites and Chylothorax: An Unusual Manifestation of Cardiac Amyloidosis. <i>Internal Medicine</i> , 2010, 49, 1763-1766.	0.3	6
311	Association between clinical characteristics and AL amyloid deposition in the kidney. <i>Heart and Vessels</i> , 2010, 25, 543-548.	0.5	10
312	Amyloid Heart Disease. <i>Progress in Cardiovascular Diseases</i> , 2010, 52, 347-361.	1.6	202
313	A Single Mutation Promotes Amyloidogenicity through a Highly Promiscuous Dimer Interface. <i>Structure</i> , 2010, 18, 563-570.	1.6	42
314	Alanine-to-threonine substitutions and amyloid diseases: Butyrylcholinesterase as a case study. <i>Chemico-Biological Interactions</i> , 2010, 187, 64-71.	1.7	40
315	Solid Organ Transplantation in AL Amyloidosis. <i>American Journal of Transplantation</i> , 2010, 10, 2124-2131.	2.6	109
316	Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients. <i>American Journal of Hematology</i> , 2010, 85, 171-173.	2.0	75
318	Primary AL amyloid polyneuropathy successfully treated with high-dose melphalan followed by autologous stem cell transplantation. <i>Muscle and Nerve</i> , 2010, 41, 138-143.	1.0	19
319	A rare case of primary systemic amyloidosis of the neck with massive cervical lymph node involvement: A case report and review of the literature. <i>Leukemia Research</i> , 2010, 34, e100-e103.	0.4	9
320	Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. <i>British Journal of Haematology</i> , 2010, 149, 334-351.	1.2	88
321	Clinical and pathological features of renal amyloidosis: An analysis of 32 patients in a single Chinese centre. <i>Nephrology</i> , 2010, 15, 102-107.	0.7	5
322	Renal biopsy is a relatively safe procedure in cases of suspected amyloidosis and a valuable tool in excluding non-AL forms of the disease. <i>Internal Medicine Journal</i> , 2010, 40, 167-168.	0.5	2
323	Robert Arthur Kyle, MD: A Conversation with the Editor. <i>Baylor University Medical Center Proceedings</i> , 2010, 23, 400-418.	0.2	0
324	Papillary Thyroid Cancer Associated With Light-Chain Amyloidosis Initially Presenting With Small-Bowel Bleeding and Protein-Losing Enteropathy. <i>Journal of Clinical Oncology</i> , 2010, 28, e557-e559.	0.8	3
325	Renal Amyloidosis and Glomerular Diseases with Monoclonal Immunoglobulin Deposition. , 2010, , 322-334.		2
326	Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2010, 17, 129-136.	1.4	27

#	ARTICLE	IF	CITATIONS
327	Systemic amyloidosis: a challenge for the rheumatologist. <i>Nature Reviews Rheumatology</i> , 2010, 6, 417-429.	3.5	71
328	Heparan Sulfate Proteoglycans in Amyloidosis. <i>Progress in Molecular Biology and Translational Science</i> , 2010, 93, 309-334.	0.9	33
329	AL ^Î (UNK) â€“ primary structure of an AL-amyloid protein presenting an organ-limited subcutaneous nodular amyloid syndrome of long duration. Case report and review. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2010, 17, 10-23.	1.4	3
331	Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2010, 85, 232-238.	1.4	69
332	Transthyretin-related amyloidoses and the heart: a clinical overview. <i>Nature Reviews Cardiology</i> , 2010, 7, 398-408.	6.1	286
333	The role of echocardiographic deformation imaging in hypertrophic myopathies. <i>Nature Reviews Cardiology</i> , 2010, 7, 384-396.	6.1	80
334	Approach to diagnosis in systemic amyloidosis: initial findings and time from symptoms onset to diagnosis (light-chain amyloidosis vs. transthyretin). Problems and observations. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2011, 18, 83-85.	1.4	10
335	Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score. <i>Mayo Clinic Proceedings</i> , 2011, 86, 12-18.	1.4	164
336	Role of 99mTc-DPD Scintigraphy in Diagnosis and Prognosis of Hereditary Transthyretin-Related Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 659-670.	2.3	264
337	Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis. <i>Archives of Cardiovascular Diseases</i> , 2011, 104, 611-618.	0.7	47
338	Manifestations ostÃ©oarticulaires des amyloses. <i>Revue Du Rhumatisme Monographies</i> , 2011, 78, 279-285.	0.0	2
339	Neuropatie periferiche nel corso delle disglobulinemie. <i>EMC - Neurologia</i> , 2011, 11, 1-14.	0.0	0
340	Amyloidogenicity and Clinical Phenotype Associated with Five Novel Mutations in Apolipoprotein A-I. <i>American Journal of Pathology</i> , 2011, 179, 1978-1987.	1.9	111
341	Cardiac Amyloidosis: A Practical Approach to Diagnosis and Management. <i>American Journal of Medicine</i> , 2011, 124, 1006-1015.	0.6	97
342	Effect of lysine modification on the stability and cellular binding of human amyloidogenic light chains. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 32-40.	1.8	6
343	Cardiomyopathies (hypertrophy and failure): What can offer cardiac magnetic resonance imaging?. <i>Presse Medicale</i> , 2011, 40, e425-e436.	0.8	4
345	Intestinal pseudo-obstruction associated with amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2011, 18, 76-78.	1.4	18
346	Amyloidosis. Also a Heart Disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 797-808.	0.4	1

#	ARTICLE	IF	CITATIONS
347	Renal failure due to primary amyloidosis: a case report and literature review. Sao Paulo Medical Journal, 2011, 129, 176-180.	0.4	2
348	¹⁸ F-FDG PET/CT in Primary AL Hepatic Amyloidosis Associated with Multiple Myeloma. Korean Journal of Radiology, 2011, 12, 634.	1.5	18
351	Guidelines for supportive care in multiple myeloma 2011. British Journal of Haematology, 2011, 154, 76-103.	1.2	176
352	Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study. European Journal of Neurology, 2011, 18, 604-610.	1.7	72
353	Utility of Combined Indexes of Electrocardiography and Echocardiography in the Diagnosis of Biopsy Proven Primary Cardiac Amyloidosis. , 2011, 16, 25-29.		23
354	De novo AL Amyloidosis in the Kidney Allograft. American Journal of Transplantation, 2011, 11, 606-612.	2.6	8
355	A Reappraisal of Immunoglobulin Variable Gene Primers and Its Impact on Assessing Clonal Relationships Between PB B Cells and BM Plasma Cells in AL Amyloidosis. Journal of Clinical Immunology, 2011, 31, 1029-1037.	2.0	3
356	How to treat patients with systemic amyloid light chain amyloidosis? Comparison of high-dose melphalan, low-dose chemotherapy and no chemotherapy in patients with or without cardiac amyloidosis. Clinical and Experimental Nephrology, 2011, 15, 486-492.	0.7	2
357	Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Annals of Hematology, 2011, 90, 101-106.	0.8	39
358	Light chain (AL) amyloidosis: update on diagnosis and management. Journal of Hematology and Oncology, 2011, 4, 47.	6.9	68
359	In the face of it all. Journal of Hospital Medicine, 2011, 6, 98-102.	0.7	0
360	Changes in serum free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. American Journal of Hematology, 2011, 86, 251-255.	2.0	78
361	Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrology Dialysis Transplantation, 2011, 26, 2032-2036.	0.4	88
362	Surgical removal of amyloid-laden lymph nodes: a possible therapeutic approach in a primary systemic AL amyloidosis patient with focal lymphadenopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 79-82.	1.4	4
363	The blue man: a novel cutaneous manifestation of systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 156-159.	1.4	2
364	Outcome in Renal AL Amyloidosis After Chemotherapy. Journal of Clinical Oncology, 2011, 29, 674-681.	0.8	126
365	Clinical Features of Renal Amyloidosis: An Analysis of 40 Patients in a 28-year Follow-up. Internal Medicine, 2011, 50, 2511-2517.	0.3	9
366	Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 152-154.	1.4	7

#	ARTICLE	IF	CITATIONS
367	Cardiac Amyloidosis. <i>Circulation</i> , 2011, 124, 1079-1085.	1.6	117
368	Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 957-970.	0.2	40
369	Spontaneous bilateral kidney rupture during autologous stem cell transplantation in a patient affected by amyloidosis. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 56-59.	1.4	0
370	Dysregulation of miRNAs in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2011, 18, 128-135.	1.4	8
371	Proteomics in Molecular Diagnosis: Typing of Amyloidosis. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-9.	3.0	25
373	Response to Letter Regarding Article, "An Unusual Heart Failure: Cardiac Amyloidosis Due to Light Chain Myeloma", <i>Circulation</i> , 2011, 124, .	1.6	0
374	Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2012, 19, 191-196.	1.4	18
375	Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. <i>Journal of Clinical Oncology</i> , 2012, 30, 989-995.	0.8	837
376	Updates in Cardiac Amyloidosis: A Review. <i>Journal of the American Heart Association</i> , 2012, 1, e000364.	1.6	204
377	Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1097-1101.	0.4	61
378	Differential diagnosis of localized and systemic amyloidosis based on coagulation and fibrinolysis parameters. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2012, 19, 61-65.	1.4	9
379	Anxiety and depression among AL amyloidosis patients: the role of cardiac symptoms. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2012, 19, 123-128.	1.4	11
380	Cancer-testis antigen expression and immunogenicity in AL amyloidosis. <i>Blood Cancer Journal</i> , 2012, 2, e90-e90.	2.8	8
381	Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1964-1968.	2.2	72
382	Immunoglobulin D amyloidosis: a distinct entity. <i>Blood</i> , 2012, 119, 44-48.	0.6	17
383	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. <i>Blood</i> , 2012, 119, 4860-4867.	0.6	119
384	How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. <i>Blood</i> , 2012, 120, 3206-3213.	0.6	132
385	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego na rok 2012. <i>Acta Haematologica Polonica</i> , 2012, 43, 7-47.	0.1	5

#	ARTICLE	IF	CITATIONS
386	Histologic remission of cardiac amyloidosis: a case report. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2012, 19, 106-109.	1.4	4
387	What do I need to know about immunoglobulin light chain (AL) amyloidosis?. <i>Blood Reviews</i> , 2012, 26, 137-154.	2.8	106
388	Significant association between renal function and amyloid-positive area in renal biopsy specimens in AL amyloidosis. <i>BMC Nephrology</i> , 2012, 13, 118.	0.8	16
389	AL Amyloidosis. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 54.	1.2	199
390	Clinical and Echocardiographic Correlates of Elevated Troponin in Amyloid Light-Chain Cardiac Amyloidosis. <i>American Journal of Cardiology</i> , 2012, 110, 1180-1184.	0.7	21
391	Osteo-articular manifestations of amyloidosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 459-475.	1.4	47
392	Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. <i>Blood</i> , 2012, 120, 4292-4295.	0.6	447
393	Amyloidosis. <i>Annals of Clinical Biochemistry</i> , 2012, 49, 229-241.	0.8	66
394	Ultrasound-guided percutaneous renal biopsy-induced accessory renal artery bleeding in an amyloidosis patient. <i>Diagnostic Pathology</i> , 2012, 7, 176.	0.9	9
395	Differences in Immunoglobulin Light Chain Species Found in Urinary Exosomes in Light Chain Amyloidosis (AL). <i>PLoS ONE</i> , 2012, 7, e38061.	1.1	36
396	A Case of Gastric Amyloidosis with Recurrent Bleeding. <i>Japanese Journal of Gastroenterological Surgery</i> , 2012, 45, 715-723.	0.0	0
397	Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. <i>Cancer</i> , 2012, 118, 6105-6109.	2.0	57
398	Molecular Imaging of Amyloidosis: Will the Heart Be the Next Target After the Brain?. <i>Current Cardiology Reports</i> , 2012, 14, 226-233.	1.3	53
399	Cardiac amyloidosis. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 4-10.	0.3	1
400	Gastrointestinal manifestation of amyloidosis. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 15-17.	0.3	2
401	Localized pleural amyloidosis: report of a case. <i>Surgery Today</i> , 2012, 42, 597-600.	0.7	3
402	Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis. <i>American Journal of Hematology</i> , 2012, 87, 51-54.	2.0	20
403	An Update on Monoclonal Gammopathy and Neuropathy. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 102-110.	2.0	63

#	ARTICLE	IF	CITATIONS
404	Amiloidosis. <i>Medicine</i> , 2013, 11, 2065-2075.	0.0	0
405	Noncontrast T1 Mapping for the Diagnosis of Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2013, 6, 488-497.	2.3	517
406	Extensive Amyloid Deposit in Bone Marrow Aspirate. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2013, 29, 187-188.	0.3	2
407	A case of fatal intrahepatic cholestasis with primary AL amyloidosis: is early diagnosis possible?. <i>Clinical Journal of Gastroenterology</i> , 2013, 6, 386-389.	0.4	1
408	Pathophysiology and treatment of systemic amyloidosis. <i>Nature Reviews Nephrology</i> , 2013, 9, 574-586.	4.1	93
410	Amyloidosis of the breast: predominantly AL type and over half have concurrent breast hematologic disorders. <i>Modern Pathology</i> , 2013, 26, 232-238.	2.9	56
411	AL amyloidosis. <i>Medicine</i> , 2013, 41, 299-301.	0.2	2
412	Metabolic and storage lung diseases: spectrum of imaging appearances. <i>Insights Into Imaging</i> , 2013, 4, 773-785.	1.6	14
413	New Insights and Modern Treatment of AL Amyloidosis. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 291-298.	1.2	21
414	Prostate amyloid tumor is a clue leading to the diagnosis of systemic AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013, 20, 193-194.	1.4	10
415	A case of chronic lymphocytic leukemia associated with systemic light chain amyloidosis. <i>Leukemia and Lymphoma</i> , 2013, 54, 2062-2064.	0.6	3
416	Cardiac amyloidosis: the heart of the matter. <i>Internal and Emergency Medicine</i> , 2013, 8, 191-203.	1.0	36
417	Clinical features and treatment outcome of primary systemic light chain amyloidosis in Korea: Results of multicenter analysis. <i>American Journal of Hematology</i> , 2013, 88, 52-55.	2.0	14
418	Relationship between monoclonal gammopathy and cardiac amyloid type. <i>Cardiovascular Pathology</i> , 2013, 22, 189-194.	0.7	52
419	Cardiac amyloidosis: A comprehensive review. <i>Cor Et Vasa</i> , 2013, 55, e60-e75.	0.1	38
420	Cardiac amyloidosis: Updates in diagnosis and management. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 528-540.	0.7	181
421	Chronic myopathy due to immunoglobulin light chain amyloidosis. <i>Molecular Genetics and Metabolism</i> , 2013, 108, 249-254.	0.5	9
422	Características clínicas de los pacientes con amiloidosis sistémicas en el periodo 2000 - 2010. <i>Revista Clinica Espanola</i> , 2013, 213, 186-193.	0.2	19

#	ARTICLE	IF	CITATIONS
423	Clinical characteristics of patients with systemic amyloidosis from 2000â€“2010. <i>Revista Cl&#x00ed;nica Espan&#x00f5;la</i> , 2013, 213, 186-193.	0.3	2
424	Current Trends in Diagnosis and Management of Cardiac Amyloidosis. <i>Current Problems in Cardiology</i> , 2013, 38, 53-96.	1.1	51
425	Sudden Death Due to Undiagnosed Primary Amyloidosis. <i>Journal of Forensic Sciences</i> , 2013, 58, S250-2.	0.9	8
426	Immunoglobulins and Laboratory Recognition of Monoclonal Proteins. , 2013, , 565-588.		1
427	Heavy chain deposition disease: an overview. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 771-778.	0.7	17
428	Amyloidosis. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, 323-345.	0.8	122
429	Light-chain amyloidosis: SCT, novel agents and beyond. <i>Bone Marrow Transplantation</i> , 2013, 48, 1022-1027.	1.3	11
430	A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?. <i>Haematologica</i> , 2013, 98, 988-992.	1.7	49
431	A clinicopathological analysis in a large cohort of Chinese patients with renal amyloid light-chain amyloidosis. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 689-697.	0.4	18
432	The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. <i>Kidney International</i> , 2013, 83, 463-470.	2.6	101
433	Skin Involvement in Primary Systemic Amyloidosis. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013005.	0.5	29
434	Thermal Stability Threshold for Amyloid Formation in Light Chain Amyloidosis. <i>International Journal of Molecular Sciences</i> , 2013, 14, 22604-22617.	1.8	24
435	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4319-4324.	0.8	193
436	Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome. <i>Journal of the American Heart Association</i> , 2013, 2, e000098.	1.6	275
437	Effect of Combined Systolic and Diastolic Functional Parameter Assessment for Differentiation of Cardiac Amyloidosis From Other Causes of Concentric Left Ventricular Hypertrophy. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 1066-1072.	1.3	150
438	Microbiologically documented infections in patients undergoing highâ€dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis. <i>Transplant Infectious Disease</i> , 2013, 15, 187-194.	0.7	4
439	The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. <i>British Journal of Haematology</i> , 2013, 161, 367-372.	1.2	36
440	Clinical profile and treatment outcomes of immunoglobulin <sc>D</sc> associated <sc>AL</sc> amyloidosis. <i>British Journal of Haematology</i> , 2013, 162, 856-858.	1.2	1

#	ARTICLE	IF	CITATIONS
441	Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013, 20, 204-211.	1.4	5
442	Fatal Cardiac and Renal Allograft Rejection With Lenalidomide Therapy for Light-Chain Amyloidosis. <i>American Journal of Transplantation</i> , 2013, 13, 2730-2733.	2.6	21
443	Diagnostic and Prognostic Value of Low QRS Voltages in Cardiac AL Amyloidosis. <i>Annals of Noninvasive Electrocardiology</i> , 2013, 18, 271-280.	0.5	75
444	Quantification of Myocardial Extracellular Volume Fraction in Systemic AL Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 34-39.	1.3	261
445	How I treat monoclonal gammopathy of renal significance (MGRS). <i>Blood</i> , 2013, 122, 3583-3590.	0.6	259
446	Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. <i>Haematologica</i> , 2013, 98, 789-792.	1.7	50
447	A prospective study of nutritional status in immunoglobulin light chain amyloidosis. <i>Haematologica</i> , 2013, 98, 136-140.	1.7	27
448	Current state of cardiac amyloidosis. <i>Current Opinion in Cardiology</i> , 2013, 28, 242-248.	0.8	34
449	Vertebra collapse due to primary amyloidosis causing neurological compromise. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013009075-bcr2013009075.	0.2	2
450	Primary Systemic Amyloidosis with Extensive Gastrointestinal Involvement. <i>Case Reports in Gastroenterology</i> , 2013, 7, 511-515.	0.3	8
451	Impact of Regional Left Ventricular Function on Outcome for Patients with AL Amyloidosis. <i>PLoS ONE</i> , 2013, 8, e56923.	1.1	23
452	Cardiac Amyloidosis: Typing, Diagnosis, Prognosis and Management. , 2013, , .		0
453	Amyloid heart disease (part 1): Epidemiology, types, clinical features and investigations. <i>British Journal of Cardiac Nursing</i> , 2014, 9, 281-286.	0.0	0
454	¹⁸ F-fluorodeoxyglucose positron emission tomography might be useful for diagnosis of hepatic amyloidosis. <i>International Medical Case Reports Journal</i> , 2014, 7, 103.	0.3	1
455	Cardiac amyloidosis. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 265-277.	0.6	21
456	A Residue-specific Shift in Stability and Amyloidogenicity of Antibody Variable Domains. <i>Journal of Biological Chemistry</i> , 2014, 289, 26829-26846.	1.6	15
457	High Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 1131-1144.	0.9	16
458	Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 261-266.	1.4	21

#	ARTICLE	IF	CITATIONS
459	Update on treatment of light chain amyloidosis. <i>Haematologica</i> , 2014, 99, 209-221.	1.7	93
460	Treatment of CMD in Myocardial Diseases. , 2014, , 219-224.		0
461	Minimally Invasive Minor Salivary Gland Biopsy for the Diagnosis of Amyloidosis in a Rheumatology Clinic. <i>ISRN Rheumatology</i> , 2014, 2014, 1-3.	1.9	17
462	Primary Systemic AL Amyloidosis Presenting as Temporal Arteritis. <i>Case Reports in Rheumatology</i> , 2014, 2014, 1-4.	0.2	4
463	How to diagnose amyloidosis. <i>Internal Medicine Journal</i> , 2014, 44, 7-17.	0.5	67
465	Amyloid nephropathy. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 97-106.	1.4	53
466	Cardiac Amyloidosis Cases with Relative Apical Sparing of Longitudinal Strain. <i>Echocardiography</i> , 2014, 31, 241-244.	0.3	5
467	Myeloma-related Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 36-47.	0.6	50
468	Amyloidosis: Review and Imaging Findings. <i>Seminars in Ultrasound, CT and MRI</i> , 2014, 35, 225-239.	0.7	22
469	Neurologic aspects of plasma cell disorders. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014, 120, 1083-1099.	1.0	21
470	Renal Amyloidosis. <i>Surgical Pathology Clinics</i> , 2014, 7, 409-425.	0.7	10
471	Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis. <i>American Journal of Hematology</i> , 2014, 89, 706-708.	2.0	4
472	The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1307-1315.	0.5	64
473	Nuclear imaging modalities for cardiac amyloidosis. <i>Journal of Nuclear Cardiology</i> , 2014, 21, 175-184.	1.4	93
474	Advanced Cardiac Amyloidosis Associated with Normal Interventricular Septal Thickness: An Uncommon Presentation of Infiltrative Cardiomyopathy. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 440-447.	1.2	30
475	Clinical Manifestations at Diagnosis in Japanese Patients with Systemic AL Amyloidosis: A Retrospective Study of 202 Cases with a Special Attention to Uncommon Symptoms. <i>Internal Medicine</i> , 2014, 53, 403-412.	0.3	31
476	Waldenström's Macroglobulinemia Accompanying Systemic Amyloidosis: The Usefulness of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Detecting Amyloid Deposits. <i>Internal Medicine</i> , 2014, 53, 2789-2793.	0.3	7
477	Marked and Rapid Regression of Hepatic Amyloid Deposition in a Patient with Systemic Light Chain (AL) Amyloidosis after High-dose Melphalan Therapy with Stem Cell Transplantation. <i>Internal Medicine</i> , 2014, 53, 1991-1995.	0.3	10

#	ARTICLE	IF	CITATIONS
480	A rare case of primary systemic amyloidosis presenting with multiorgan involvement. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1238-1239.	1.3	0
481	Primary systemic amyloidosis initially presenting with digestive symptoms: a case report and review of the literature. <i>Diagnostic Pathology</i> , 2015, 10, 174.	0.9	7
482	Effect of single point mutations in a form of systemic amyloidosis. <i>Protein Science</i> , 2015, 24, 1451-1462.	3.1	8
484	A Case of Amyloid Goiter Masquerading as Graves' Disease. <i>International Journal of Thyroidology</i> , 2015, 8, 221.	0.1	0
485	Stabilisation of Laryngeal AL Amyloidosis with Long Term Curcumin Therapy. <i>Case Reports in Hematology</i> , 2015, 2015, 1-4.	0.3	7
486	Amyloidosis of the renal pelvis: a harbinger of mammary carcinoma?. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014207955-bcr2014207955.	0.2	2
487	High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. <i>Bone Marrow Transplantation</i> , 2015, 50, 668-672.	1.3	7
488	Estimation of Daily Proteinuria in Patients with Amyloidosis by Using the Protein-To-Creatinine ratio in Random Urine Samples. <i>Rare Tumors</i> , 2015, 7, 16-19.	0.3	8
489	Myeloma-associated systemic amyloidosis masquerading as NASH-associated cirrhosis and diabetic microvascular complications. <i>Oxford Medical Case Reports</i> , 2015, 2015, 258-261.	0.2	1
490	A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. <i>European Heart Journal</i> , 2015, 36, 1098-1105.	1.0	129
491	Autologous Stem Cell Transplantation in Patients With Primary Systemic Amyloidosis: Experience of a Tertiary Hospital. <i>Transplantation Proceedings</i> , 2015, 47, 2661-2664.	0.3	1
492	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. <i>American Journal of Hematology</i> , 2015, 90, 181-186.	2.0	76
493	11C-Pittsburgh B PET Imaging in Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 50-59.	2.3	135
494	Management of systemic <sc>AL</sc> amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015, 45, 371-382.	0.5	19
495	Differential Effects on Light Chain Amyloid Formation Depend on Mutations and Type of Glycosaminoglycans. <i>Journal of Biological Chemistry</i> , 2015, 290, 4953-4965.	1.6	36
496	The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 120-126.	1.4	46
497	Treatment of Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1054-1081.	1.4	106
498	Improving strategies for the diagnosis of cardiac amyloidosis. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 945-961.	0.6	6

#	ARTICLE	IF	CITATIONS
499	Outcomes After Heart Transplantation for Amyloid Cardiomyopathy in the Modern Era. <i>American Journal of Transplantation</i> , 2015, 15, 650-658.	2.6	74
500	Recent advances in the understanding of immune-mediated nephrotic syndrome: diagnostic and prognostic implications. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 489-500.	1.3	2
501	New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies. <i>Nephrologie Et Therapeutique</i> , 2015, 11, 135-143.	0.2	19
502	Characteristics and Long-Term Outcome of Patients with Systemic Immunoglobulin Light-Chain Amyloidosis. <i>Acta Haematologica</i> , 2015, 133, 336-346.	0.7	5
503	Guidelines on the diagnosis and investigation of AL amyloidosis. <i>British Journal of Haematology</i> , 2015, 168, 207-218.	1.2	122
504	Flow cytometry in immunoglobulin light chain amyloidosis: Short review. <i>Leukemia Research</i> , 2015, 39, 1131-1136.	0.4	10
505	The Antibody Light-Chain Linker Is Important for Domain Stability and Amyloid Formation. <i>Journal of Molecular Biology</i> , 2015, 427, 3572-3586.	2.0	21
506	Manifestaciones osteoarticulares de la amiloidosis. <i>EMC - Aparato Locomotor</i> , 2015, 48, 1-10.	0.1	0
507	Pulmonary Hypertension Complicating Multiple Myeloma. <i>Pulmonary Circulation</i> , 2015, 5, 590-597.	0.8	18
508	The Authors Reply. <i>Kidney International</i> , 2015, 88, 202.	2.6	0
509	Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the V _L framework using a structure-guided approach. <i>MAbs</i> , 2015, 7, 1058-1071.	2.6	26
510	Dysproteinemias and Kidney Disease. , 2015, , 251-277.		0
511	Emerging treatments for amyloidosis. <i>Kidney International</i> , 2015, 87, 516-526.	2.6	25
512	Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD). <i>Pathologie Et Biologie</i> , 2015, 63, 17-20.	2.2	8
513	Amyloid Neuropathy. , 2015, , 295-309.		0
514	Pathophysiology and treatment of cardiac amyloidosis. <i>Nature Reviews Cardiology</i> , 2015, 12, 91-102.	6.1	123
515	Cancer and Chronic Kidney Disease. , 2015, , 571-584.		1
516	Acute liver failure due to primary amyloidosis in a nephrotic syndrome: a swiftly progressive course. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016214392.	0.2	5

#	ARTICLE	IF	CITATIONS
517	Amyloid Nephropathy: A Practical Diagnostic Approach and Review on Pathogenesis. , 0, , .		2
519	Comparison of Free Light Chain Assays. American Journal of Clinical Pathology, 2016, 146, 78-85.	0.4	8
520	Induction therapy preâ€autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. American Journal of Hematology, 2016, 91, 984-988.	2.0	45
521	New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis. Current Heart Failure Reports, 2016, 13, 267-272.	1.3	8
522	Liver Transplantation Is a Potential Treatment Option for Systemic Light Chain Amyloidosis Patients with Dominant Hepatic Involvement: A Case Report and Analytical Review of the Literature. Internal Medicine, 2016, 55, 1585-1590.	0.3	8
523	Oral purpura as the first manifestation of primary systemic amyloidosis. British Journal of Oral and Maxillofacial Surgery, 2016, 54, 697-699.	0.4	3
524	Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis. Bone Marrow Transplantation, 2016, 51, 1318-1322.	1.3	6
525	LGE Provides Incremental Prognostic Information OverÂSerum Biomarkers in ALÂCardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2016, 9, 680-686.	2.3	68
526	^{99m} Tc-DPD scintigraphy as a novel imaging modality for identification of skeletal muscle amyloid deposition in light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 134-135.	1.4	9
527	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
528	Abnormal stress echocardiography findings in cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 124-131.	1.4	7
529	Primary AL amyloidosis presenting as lower motor neuron disease. Journal of the Neurological Sciences, 2016, 364, 177-179.	0.3	3
530	Concomitant use of Congo red staining and confocal laser scanning microscopy to detect amyloidosis in oral biopsy: A clinicopathological study of 16 patients. Ultrastructural Pathology, 2016, 40, 86-91.	0.4	3
531	Respiratory failure caused by amyloid myopathy. Medicina Cl�nica (English Edition), 2016, 146, e25-e26.	0.1	1
532	The pathological diagnosis of nerve biopsies: a practical approach. Diagnostic Histopathology, 2016, 22, 333-344.	0.2	4
533	Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 214-220.	1.4	8
534	2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 168-177.	1.4	25
535	Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994â€2009. Bone Marrow Transplantation, 2016, 51, 1569-1572.	1.3	16

#	ARTICLE	IF	CITATIONS
537	Monoclonal IgM-related AL amyloidosis. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 241-248.	0.7	29
538	Recent advances in the noninvasive strategies of cardiac amyloidosis. <i>Heart Failure Reviews</i> , 2016, 21, 703-721.	1.7	12
539	Perspectives in Pediatric Pathology, Chapter 22. Testicular Involvement in Systemic Diseases. <i>Pediatric and Developmental Pathology</i> , 2016, 19, 431-451.	0.5	0
540	Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2280-2287.	2.2	37
542	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. <i>Blood</i> , 2016, 127, 2936-2938.	0.6	17
543	The evaluation of renal hemodynamics changes in Familial Mediterranean fever with color Doppler sonography. <i>Renal Failure</i> , 2016, 38, 1161-1166.	0.8	3
544	Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox?. <i>Annals of Neurology</i> , 2016, 80, 401-411.	2.8	17
545	Prevalence of amyloid and positive Congo red frequency among routine surgical specimens. <i>Journal of Histotechnology</i> , 2016, 39, 88-92.	0.2	0
546	Primary Amyloidosis Discovered During Pregnancy. <i>Therapeutic Apheresis and Dialysis</i> , 2016, 20, 209-211.	0.4	0
547	Amyloid light-chain amyloidosis presenting as abdominal bloating: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 68.	0.4	11
548	Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2941-2948.	1.2	84
549	European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin-Related Light Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2037-2045.	0.8	60
550	Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview. <i>Gene</i> , 2016, 591, 490-498.	1.0	6
551	Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy. <i>Acta Haematologica</i> , 2016, 135, 172-190.	0.7	57
552	Clinical Characteristics and Treatment Outcome of Chinese Patients With Systemic Amyloid Light-Chain Amyloidosis: A Retrospective Single-Center Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 104-110.	0.2	13
554	The eye and the skin in nonendocrine metabolic disorders. <i>Clinics in Dermatology</i> , 2016, 34, 166-182.	0.8	7
555	Multisystem diseases affecting the skin and eye. <i>Clinics in Dermatology</i> , 2016, 34, 214-241.	0.8	6
556	Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy. <i>Bone Marrow Transplantation</i> , 2016, 51, 732-734.	1.3	3

#	ARTICLE	IF	CITATIONS
557	A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1073-1082.	2.2	7
558	A Stable Mutant Predisposes Antibody Domains to Amyloid Formation through Specific Non-Native Interactions. <i>Journal of Molecular Biology</i> , 2016, 428, 1315-1332.	2.0	20
559	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289.	0.4	25
560	Monoclonal gammopathy: The good, the bad and the ugly. <i>Blood Reviews</i> , 2016, 30, 223-231.	2.8	54
561	Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 796-801.	2.0	16
562	Light-chain cardiac amyloidosis. <i>Current Problems in Cancer</i> , 2017, 41, 144-156.	1.0	19
563	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017, 49, 545-551.	1.5	45
564	Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?. <i>Blood Reviews</i> , 2017, 31, 261-270.	2.8	19
565	Amyloid heart disease: genetics translated into disease-modifying therapy. <i>Heart</i> , 2017, 103, 812-817.	1.2	20
566	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.	2.0	16
567	Flow cytometry-based immunophenotypic analysis of primary systemic light chain amyloidosis. <i>Oncology Letters</i> , 2017, 13, 2691-2697.	0.8	4
568	Glomerular Diseases Associated with Malignancies. , 2017, , 1-40.		0
569	Vascular Pathology Related to Extracellular Material Accumulation. , 2017, , 219-228.		0
570	Outcome of very young (â‰¥40 years) patients with immunoglobulin light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 50-51.	1.4	5
571	Targeted Nuclear Imaging Probes for Cardiac Amyloidosis. <i>Current Cardiology Reports</i> , 2017, 19, 59.	1.3	19
572	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. <i>Blood</i> , 2017, 130, 597-605.	0.6	108
574	Stem cell transplantation for immunoglobulin light chain amyloidosis. <i>Current Problems in Cancer</i> , 2017, 41, 129-137.	1.0	9
575	New and developing therapies for AL amyloidosis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 139-149.	0.9	14

#	ARTICLE	IF	CITATIONS
576	Apolipoprotein A-1-related amyloidosis 2 case reports and review of the literature. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	9.4	15
577	Paraprotein deposits in the skin. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 1145-1158.	0.6	21
578	A longitudinal evaluation of health-related quality of life in patients with <scp>AL</scp> amyloidosis: associations with health outcomes over time. <i>British Journal of Haematology</i> , 2017, 179, 461-470.	1.2	27
579	Restrictive Cardiomyopathy. <i>Circulation Research</i> , 2017, 121, 819-837.	2.0	219
580	Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. <i>Contemporary Clinical Trials Communications</i> , 2017, 8, 33-38.	0.5	17
581	Effect of amino acid mutations on the conformational dynamics of amyloidogenic immunoglobulin light-chains: A combined NMR and in silico study. <i>Scientific Reports</i> , 2017, 7, 10339.	1.6	4
582	Heat-induced native dimerization prevents amyloid formation by variable domain from immunoglobulin light-chain <scp>REI</scp>. <i>FEBS Journal</i> , 2017, 284, 3114-3127.	2.2	4
583	Contribution of human smooth muscle cells to amyloid angiopathy in AL (light-chain) amyloidosis. <i>Ultrastructural Pathology</i> , 2017, 41, 358-368.	0.4	9
584	News in AL Amyloidosis ASH 2016. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 66-71.	0.3	4
585	Bortezomib+dexamethasone versus high-dose melphalan for Japanese patients with systemic light-chain (AL) amyloidosis: a retrospective single-center study. <i>International Journal of Hematology</i> , 2017, 105, 341-348.	0.7	8
586	Renal Disease Associated with Monoclonal Gammopathy. , 2017, , 163-194.		0
587	Extreme Amyloid Depositions in the Calvarium and Dura Associated With Plasma Cell Myeloma. <i>International Journal of Surgical Pathology</i> , 2017, 25, 163-164.	0.4	1
588	Glomerular Diseases. , 2017, , 19-294.e1.		1
589	Bronchoscopic Diagnosis and Treatment of Primary Tracheobronchial Amyloidosis: A Retrospective Analysis from China. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	16
590	Restrictive Cardiomyopathies: The Importance of Noninvasive Cardiac Imaging Modalities in Diagnosis and Treatment—A Systematic Review. <i>Radiology Research and Practice</i> , 2017, 2017, 1-14.	0.6	25
591	My Patient with Monoclonal Gammopathy of Undetermined Significance has a Kidney Problem. <i>Journal of Onco-Nephrology</i> , 2017, 1, 18-23.	0.3	3
592	The risk of renal disease is increased in lambda myeloma with bone marrow amyloid deposits. <i>Journal of Blood Medicine</i> , 2017, Volume 8, 29-34.	0.7	1
593	Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 79-85.	1.4	17

#	ARTICLE	IF	CITATIONS
594	Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 549-559.	0.6	22
595	Cerebrospinal fluid findings in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathies. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018, 146, 125-138.	1.0	34
596	Supportive Care in Multiple Myeloma. , 2018, , 595-607.		0
597	Plasma cell diseases and organ transplant: A comprehensive review. <i>American Journal of Transplantation</i> , 2018, 18, 1046-1058.	2.6	9
598	Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. <i>Clinical Biochemistry</i> , 2018, 51, 38-47.	0.8	43
599	Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis. <i>British Journal of Haematology</i> , 2018, 182, 145-148.	1.2	20
600	Right ventricular involvement evaluated by cardiac magnetic resonance imaging predicts mortality in patients with light chain amyloidosis. <i>Heart and Vessels</i> , 2018, 33, 170-179.	0.5	28
601	Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 452-461.	3.3	51
602	Neurologic Complications of Plasma Cell Dyscrasias. , 2018, , 583-595.		1
603	Structure and energetic basis of overrepresented λ light chain in systemic light chain amyloidosis patients. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 2294-2303.	1.8	6
604	Case Report: Treatment of light chain amyloidosis with daratumumab monotherapy in two patients. <i>European Journal of Haematology</i> , 2018, 100, 386-388.	1.1	17
605	Dysproteinemias and Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 128-139.	2.2	48
606	Light Chain (AL) Amyloidosis: The Journey to Diagnosis. <i>Patient</i> , 2018, 11, 207-216.	1.1	78
608	Mortality and healthcare costs in Medicare beneficiaries with AL amyloidosis. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 1053-1062.	0.6	6
609	Patient-reported distress is prevalent in systemic light chain (AL) amyloidosis but not determined by severity of disease. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 129-134.	1.4	6
610	Epidemiology of AL amyloidosis: a real-world study using US claims data. <i>Blood Advances</i> , 2018, 2, 1046-1053.	2.5	260
611	Atraumatic Splenic Rupture Due to Ectopic Extramedullary Hematopoiesis after Autologous Stem Cell Transplantation in a Patient with AL Amyloidosis. <i>Internal Medicine</i> , 2018, 57, 399-402.	0.3	4
612	Amyloidosis cardiomyopathy. <i>Current Opinion in Cardiology</i> , 2018, 33, 571-579.	0.8	53

#	ARTICLE	IF	CITATIONS
613	Current and future circulating biomarkers for cardiac amyloidosis. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1133-1141.	2.8	10
614	In Silico Methods in Antibody Design. <i>Antibodies</i> , 2018, 7, 22.	1.2	27
615	Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan. <i>Internal Medicine</i> , 2018, 57, 181-187.	0.3	47
616	MRI feature tracking strain is prognostic for all-cause mortality in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 101-108.	1.4	16
617	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e006588.	1.3	51
618	Increased Prognostic Value of Query Amyloid Late Enhancement Score in Light-Chain Cardiac Amyloidosis. <i>Circulation Journal</i> , 2018, 82, 739-746.	0.7	15
619	Right Heart Involvement in Haematologic Disorders. , 2018, , 455-473.		0
620	Ocular Adnexal Amyloidosis: A Mass Spectrometric Analysis. <i>American Journal of Ophthalmology</i> , 2018, 193, 28-32.	1.7	17
621	An update on paraprotein-related renal pathology. <i>Diagnostic Histopathology</i> , 2019, 25, 408-421.	0.2	4
622	Pharyngo-laryngeal involvement in systemic amyloidosis with cardiac involvement: a prospective observational study. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 216-224.	1.4	11
623	Hematopoietic Cell Transplantation for Light-Chain Amyloidosis. , 2019, , 255-261.		0
624	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019, 187, 588-594.	1.2	40
625	Should Patients With Cardiac Amyloidosis be Prioritized for Heart Transplantation?. <i>Journal of Cardiac Failure</i> , 2019, 25, 772-773.	0.7	1
626	A risk stratification for systemic immunoglobulin light-chain amyloidosis with renal involvement. <i>British Journal of Haematology</i> , 2019, 187, 459-469.	1.2	7
627	<p>Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 431-439.	0.7	13
628	A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis. <i>JACC: Heart Failure</i> , 2019, 7, 958-966.	1.9	31
629	Phenome-wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the genetics of hereditary and wildtype transthyretin amyloidoses. <i>Human Genetics</i> , 2019, 138, 1331-1340.	1.8	14
630	Amyloidosis: diagnosis and new therapies for a misunderstood and misdiagnosed disease. <i>Neurodegenerative Disease Management</i> , 2019, 9, 289-299.	1.2	7

#	ARTICLE	IF	CITATIONS
631	The efficacy and safety of bortezomib-based chemotherapy for immunoglobulin light chain amyloidosis: A systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2019, 69, 32-41.	1.0	1
632	Diagnosis and treatment of heart failure in hereditary transthyretin amyloidosis. <i>Clinical Autonomic Research</i> , 2019, 29, 45-53.	1.4	8
633	Light-chain amyloidosis with renal involvement: renal outcomes and validation of two renal staging systems in the Chinese population. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 186-191.	1.4	5
634	Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2019, 54, 1295-1303.	1.3	6
635	Incidentally Detected Amyloid Light-Chain Amyloidosis Caused by Monoclonal Gammopathy of Undetermined Significance: Possible Time-Dependent Change in Colonic Findings. <i>Case Reports in Gastroenterology</i> , 2019, 12, 737-746.	0.3	9
636	Cyclophosphamide+ Thalidomide+ Dexamethasone Versus Melphalan+ Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients. <i>Clinical Therapeutics</i> , 2019, 41, 1186-1198.	1.1	10
637	Amyloid in parenchymal organs in gelsolin (AGel) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 118-124.	1.4	10
638	Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis. <i>American Journal of Transplantation</i> , 2019, 19, 2900-2909.	2.6	11
639	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 553-576.	2.9	224
640	Glomerular Diseases Associated with Malignancies. , 2019, , 691-734.		0
642	Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body ¹⁸ F-Florbetapir PET/CT. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1234-1239.	2.8	54
643	Amyloid Neuropathy. , 2019, , 83-97.		0
644	Nonproteinuric renal amyloidosis in Waldenström's macroglobulinemia. <i>Nephrology</i> , 2019, 24, 490-491.	0.7	0
645	Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy: A Single-Center Cohort Study of 227 Patients. <i>Circulation Journal</i> , 2019, 83, 775-782.	0.7	8
646	Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. <i>Mayo Clinic Proceedings</i> , 2019, 94, 465-471.	1.4	87
647	Light Chain (AL) Amyloidosis and the Kidney. , 2019, , 559-568.		0
648	Myeloma-Associated Glomerular Disease. , 2019, , 617-631.		0
649	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483.	1.4	59

#	ARTICLE	IF	CITATIONS
650	Typing of hereditary renal amyloidosis presenting with isolated glomerular amyloid deposition. <i>BMC Nephrology</i> , 2019, 20, 476.	0.8	3
651	High sensitivity M α protein detection in a case of light α chain cardiac amyloidosis without evidence of plasma cell dyscrasia. <i>American Journal of Hematology</i> , 2019, 94, 619-621.	2.0	1
652	State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 158-173.	1.4	82
653	Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis. <i>Acta Haematologica</i> , 2019, 141, 93-106.	0.7	74
655	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. <i>Nature Reviews Nephrology</i> , 2019, 15, 45-59.	4.1	330
656	Cutaneous light chain amyloidosis with multiple myeloma: A concise review. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 71-81.	0.6	24
657	Nuclear imaging of cardiac amyloidosis. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 505-508.	1.4	16
658	Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1806-1815.	0.8	60
659	Cancer and Chronic Kidney Disease. , 2020, , 899-917.		1
660	New developments in diagnosis, risk assessment and management in systemic amyloidosis. <i>Blood Reviews</i> , 2020, 40, 100636.	2.8	28
661	Amyloid Cardiomyopathy. <i>Heart Lung and Circulation</i> , 2020, 29, 575-583.	0.2	15
662	Systemic light chain amyloidosis. , 2020, , 67-75.e3.		0
663	Hiding in Plain Sight: Cardiac Amyloidosis, an Emerging Epidemic. <i>Canadian Journal of Cardiology</i> , 2020, 36, 373-383.	0.8	5
665	Amyloid light α chain amyloidosis with haemorrhagic bullous eruption disclosing multiple myeloma. <i>International Wound Journal</i> , 2020, 17, 510-513.	1.3	2
666	Massive Hepatomegaly Secondary to Amyloidosis with Normal Liver Chemistries. <i>Case Reports in Gastroenterology</i> , 2020, 14, 271-278.	0.3	0
667	Importance of pleural findings in patients with amyloid cardiomyopathy complicated with refractory pleural effusion. <i>Journal of Cardiology Cases</i> , 2020, 21, 205-208.	0.2	1
668	Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 742-761.	1.0	31
669	Types of M protein and clinicopathological profiles in patients with monoclonal gammopathy of renal significance. <i>Journal of Nephrology</i> , 2020, 34, 1137-1146.	0.9	2

#	ARTICLE	IF	CITATIONS
670	Diagnosis and treatment of transthyretin-related amyloidosis cardiomyopathy. <i>Clinical Cardiology</i> , 2020, 43, 1223-1231.	0.7	10
671	Non-invasive detection and differentiation of cardiac amyloidosis using ^{99m} Tc-pyrophosphate scintigraphy and ¹¹ C-Pittsburgh compound B PET imaging. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 266-274.	1.4	24
672	How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e826-e831.	0.2	5
673	Peripheral Nervous System Involvement. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 1091-1098.	0.9	1
674	Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 1145-1159.	0.9	8
675	Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 201.	0.4	2
676	Renal Involvement in Systemic Amyloidosis Caused by Monoclonal Immunoglobulins. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 1069-1079.	0.9	3
677	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020, 10, 124.	2.8	12
678	The prognostic value of right ventricular deformation derived from cardiac magnetic resonance tissue tracking for all-cause mortality in light-chain amyloidosis patients. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 161-172.	0.7	11
679	Updates in the Diagnosis and Management of AL Amyloidosis. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 155-167.	1.2	10
680	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2020, 95, 944-954.	1.4	7
681	Confirming the Diagnosis of Amyloidosis. <i>Acta Haematologica</i> , 2020, 143, 312-321.	0.7	53
682	Solid Organ Transplantation in Amyloidosis. <i>Acta Haematologica</i> , 2020, 143, 352-364.	0.7	10
683	Proteomics-inspired precision medicine for treating and understanding multiple myeloma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 67-85.	0.4	7
684	Gateway and journey of patients with cardiac amyloidosis. <i>ESC Heart Failure</i> , 2020, 7, 2418-2430.	1.4	17
685	Time to Redefine Risk-Stratification and Response Criteria in Immunoglobulin Light Chain Amyloidosis?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e769-e776.	0.2	2
686	Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. <i>European Journal of Heart Failure</i> , 2020, 22, 1852-1862.	2.9	82
687	A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients ineligible for autologous stem cell transplantation due to severe cardiac involvement or advanced disease. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 119-127.	1.4	1

#	ARTICLE	IF	CITATIONS
688	Clinical Analysis of Cardiac Involvement in 53 Patients With Multiple Myeloma Coexistent With Light Chain Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 519-525.e1.	0.2	6
689	Supportive Care in AL Amyloidosis. <i>Acta Haematologica</i> , 2020, 143, 335-342.	0.7	11
690	Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 50-55.	1.4	28
691	A unique case of light chain (AL) amyloidosis masquerading as hypophosphatemic osteomalacia. <i>Osteoporosis International</i> , 2021, 32, 387-392.	1.3	2
693	Primary Restrictive, Infiltrative, and Storage Cardiomyopathies. , 2021, , 290-307.		0
694	Neuromuscular amyloidosis: Unmasking the master of disguise. <i>Muscle and Nerve</i> , 2021, 64, 23-36.	1.0	23
696	Amyloid cranial polyneuropathy: A rare neurological presentation of immunoglobulin light chain amyloidosis. <i>Aging Medicine (Milton (N S W))</i> , 2021, 4, 61-65.	0.9	1
697	Coagulation Abnormalities in Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 377-387.	1.4	12
698	A review of the criteria for non-invasive diagnosis of cardiac transthyretin amyloidosis. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 87-94.	0.5	2
699	The Role of Light Kappa and Lambda Chains in Heart Function Assessment in Patients with AL Amyloidosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1274.	1.0	4
700	Using digital whole-slide images to evaluate renal amyloid deposition and its association with clinical features and outcomes of AL amyloidosis. <i>Journal of Nephrology</i> , 2021, 34, 1747-1756.	0.9	1
701	Incidence rate of hospitalization and mortality in the first year following initial diagnosis of cardiac amyloidosis in the US claims databases. <i>Current Medical Research and Opinion</i> , 2021, 37, 1275-1281.	0.9	6
703	Systemic AL amyloidosis presenting with diffuse alveolar septal involvement and respiratory failure: a case report and review of the literature. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	0
704	A rare case report with diffuse "sclerodermoid appearance" due to systemic amyloidosis. <i>Australasian Journal of Dermatology</i> , 2021, 62, e458-e460.	0.4	0
705	Revisión sobre enfermedades infiltrativas sistémicas y patologías endocrínicas asociadas. <i>Endocrinología, Diabetes Y Nutrición</i> , 2021, 68, 312-320.	0.1	0
706	Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 668-678.	0.7	2
707	The Clinical Characteristics and Prognosis of Chinese Patients with Light-Chain Amyloidosis: A Retrospective Multicenter Analysis. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, 38, 444-453.	0.3	2
708	Gastrointestinal Amyloidosis in Biclonal Gammopathy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e606-e610.	0.2	0

#	ARTICLE	IF	CITATIONS
709	Cardiac Amyloidosis Presenting with Pre-Excitation Syndrome, Heart Failure, and Severe Factor X Deficiency as Part of Systemic Amyloid Light-Chain (AL) Amyloidosis – A Fatal Combination. American Journal of Case Reports, 2021, 22, e933398.	0.3	1
710	Echocardiographic assessment of cardiac amyloidosis. Heart Failure Reviews, 2022, 27, 1505-1513.	1.7	7
711	Prognostic Value of Circulating sST2 for the Prediction of Mortality in Patients With Cardiac Light-Chain Amyloidosis. Frontiers in Cardiovascular Medicine, 2020, 7, 597472.	1.1	3
712	Autopsy findings in a patient with primary systemic AL (kappa light chain) amyloidosis. Autopsy and Case Reports, 2021, 11, e2021273.	0.2	4
714	Immunoglobulin Light Chain and Systemic Light-Chain Amyloidosis. , 2007, , 183-197.		2
715	The Amyloidoses. , 2008, , 533-542.		1
716	Bleeding Disorders Associated with Cancer Dysproteinemias. Cancer Treatment and Research, 2009, 148, 295-304.	0.2	5
718	Secondary, AA, Amyloidosis. , 2010, , 179-189.		2
719	Diagnosis and Classification. , 2010, , 33-48.		2
720	Supportive Care for Amyloidosis. , 2010, , 65-75.		1
721	Amyloid Heart Disease. , 2010, , 107-128.		5
722	Urinary tract. , 2011, , 1101-1286.		8
723	Plasma Cell Neoplasms. , 2011, , 410-435.		3
724	Amyloidosis and Neuropathy. , 2005, , 2427-2451.		25
725	Maldigestion and Malabsorption. , 2010, , 1735-1767.e7.		10
726	Renal Disease in Cancer Patients. , 2012, , 1536-1552.		1
727	Myocardial Edema and Prognosis in Amyloidosis. Journal of the American College of Cardiology, 2018, 71, 2919-2931.	1.2	145
728	Kidney and liver involvement in monoclonal light chain disorders. Seminars in Nephrology, 2002, 22, 319-330.	0.6	84

#	ARTICLE	IF	CITATIONS
729	Dermatopathologic Findings in 20 Cases of Systemic Amyloidosis. American Journal of Dermatopathology, 1998, 20, 438-442.	0.3	32
730	Amyloidoma of Bone, A Plasma Cell/Plasmacytoid Neoplasm. American Journal of Surgical Pathology, 1997, 21, 179-186.	2.1	81
731	Radionuclide Imaging in Primary Amyloidosis with Liver Involvement. Clinical Nuclear Medicine, 1998, 23, 374-376.	0.7	1
732	Hepatic Amyloidosis Presenting with Severe Intrahepatic Cholestasis. Journal of Clinical Gastroenterology, 1996, 23, 134-136.	1.1	22
733	Primary Systemic Amyloidosis With Giant Hepatomegaly and a Swiftly Progressive Course. Journal of Clinical Gastroenterology, 1997, 24, 173-175.	1.1	17
734	PROGRESSION OF VENTRICULAR WALL THICKENING AFTER LIVER TRANSPLANTATION FOR FAMILIAL AMYLOIDOSIS1. Transplantation, 1997, 64, 74-80.	0.5	165
735	EFFECT OF ORTHOTOPIC LIVER TRANSPLANTATION ON THE PROGRESSION OF FAMILIAL AMYLOIDOTIC POLYNEUROPATHY. Transplantation, 1998, 65, 918-925.	0.5	117
736	Adnexal mass secondary to extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with associated amyloid deposition. BMJ Case Reports, 2014, 2014, bcr2014206699-bcr2014206699.	0.2	8
737	Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract. BMJ Case Reports, 2011, 2011, bcr0320114007-bcr0320114007.	0.2	1
738	A rare cause of dysphagia and gastroparesis. BMJ Case Reports, 2009, 2009, bcr0720080358-bcr0720080358.	0.2	4
740	Angina Pectoris and Progressive Fatigue in a 61-Year-Old Man. Circulation, 1996, 94, 3376-3381.	1.6	12
741	Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood, 2020, 136, 71-80.	0.6	146
742	Kinetics of Central Nervous System Microglial and Macrophage Engraftment: Analysis Using a Transgenic Bone Marrow Transplantation Model. Blood, 1997, 90, 986-993.	0.6	12
743	Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. Blood, 1998, 91, 3662-3670.	0.6	5
744	Long-Term Survival (10 Years or More) in 30 Patients With Primary Amyloidosis. Blood, 1999, 93, 1062-1066.	0.6	6
745	Mutations in Specific Structural Regions of Immunoglobulin Light Chains Are Associated with Free Light Chain Levels in Patients with AL Amyloidosis. PLoS ONE, 2009, 4, e5169.	1.1	72
746	Predictive Value of Assessing Diastolic Strain Rate on Survival in Cardiac Amyloidosis Patients with Preserved Ejection Fraction. PLoS ONE, 2014, 9, e115910.	1.1	31
747	Utility of abdominal skin plus subcutaneous fat and rectal mucosal biopsy in the diagnosis of AL amyloidosis with renal involvement. PLoS ONE, 2017, 12, e0185078.	1.1	18

#	ARTICLE	IF	CITATIONS
748	Lenalidomide Desensitization in Systemic Light-Chain Amyloidosis With Multi-Organ Involvement. <i>Journal of Clinical Medicine Research</i> , 2015, 7, 807-811.	0.6	4
749	Gastrointestinal Tract Amyloidosis Presenting With Pneumatosis Intestinalis. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 654-658.	0.6	8
750	Myocardial amyloidosis following multiple myeloma in a 38-year-old female patient: A case report. <i>Open Medicine (Poland)</i> , 2020, 15, 396-402.	0.6	3
751	Cardiac Amyloid " An Update. <i>European Cardiology Review</i> , 2015, 10, 113.	0.7	6
752	Amyloid Formation in Light Chain Amyloidosis. <i>Current Topics in Medicinal Chemistry</i> , 2013, 12, 2523-2533.	1.0	57
753	Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis. <i>International Journal of Heart Failure</i> , 2020, 2, 231.	0.9	11
754	A case report of localized gastric amyloidosis. <i>World Journal of Gastroenterology</i> , 2003, 9, 2632.	1.4	36
755	Multiple myeloma involving mandible: In an elderly female. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2015, 7, 763.	0.2	5
756	Amyloidosis involving the respiratory system: 5-year's experience of a multi-disciplinary group's activity. <i>Annals of Thoracic Medicine</i> , 2015, 10, 212.	0.7	12
757	Rare presentation of primary (AL) amyloidosis as gastrointestinal hemorrhage without systemic involvement. <i>World Journal of Gastrointestinal Endoscopy</i> , 2014, 6, 144.	0.4	9
758	Amyloidosis: an unusual cause of portal hypertension. <i>Autopsy and Case Reports</i> , 2016, 6, 9-18.	0.2	10
759	Diagnostic and prognostic value of cardiac imaging in amyloidosis. <i>World Journal of Cardiology</i> , 2020, 12, 599-614.	0.5	5
760	Sequence of Testing for Monoclonal Gammopathies. <i>Archives of Pathology and Laboratory Medicine</i> , 1999, 123, 114-118.	1.2	110
761	Current Updates on the Management of AL Amyloidosis. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021, 10, 147-161.	0.4	9
762	Common Factors of Alzheimer's Disease and Rheumatoid Arthritis Pathomechanism and Treatment. <i>Molecules</i> , 2021, 26, 6038.	1.7	9
764	Multiple Myeloma and Related Disorders. , 2001, , 269-288.		2
765	A Case of Primary Systemic Amyloidosis with Pruritus, Successfully Treated with Ultraviolet B.. <i>Nishinon Journal of Dermatology</i> , 2001, 63, 391-394.	0.0	2
766	Ablagerungsdermatosen, Hautveränderungen bei Stoffwechselstörungen und Mangelsyndromen. , 2002, , 749-771.		0

#	ARTICLE	IF	CITATIONS
767	Treating primary systemic amyloidosis with stem cell transplantation: outcomes in renal amyloidosis. , 2003, , 227-234.		0
768	Immunoglobulin light chain amyloidosis and the kidney. , 2003, , 215-226.		0
769	Multiple Myeloma and Other Plasma Cell Dyscrasias. , 2003, , 319-328.		0
770	Clinical features and management of amyloidosis. , 2003, , 187-202.		0
771	Immunoglobulin Light Chain Amyloidosis (Primary Amyloidosis, AL). , 2004, , 157-195.		1
772	Plasma Cell Proliferations. , 2004, , 364-378.		1
773	Aggressive Light Chain Amyloidosis Cases have Unstable Immunoglobulin Light Chains. , 2004, , 55-57.		0
775	Enfermedades glomerulares secundarias. , 2006, , 121-276.		0
776	A case of primary amyloidosis developing acute liver failure. Acta Hepatologica Japonica, 2006, 47, 22-29.	0.0	2
777	Restrictive Cardiomyopathy: Diagnosis and Prognostic Implications. , 2007, , 679-709.		0
779	AL (Immunoglobulin Light-Chain) Amyloidosis. , 2008, , 551-569.		1
780	Vaskulitiden und Systemerkrankungen. , 2008, , 417-505.		0
781	The Amyloidoses. , 2008, , 533-542.		0
783	Acute Heart Failure and Systemic Diseases. , 2008, , 306-322.		0
784	An Unusual Presentation and Etiology of Hypotension Seen in Nephrotic Syndrome. , 2009, 13, 55-7.		0
785	Assessing Response and Prognosis in AL Amyloidosis. , 2010, , 77-93.		0
786	Clinical Features of AL Amyloidosis Diagnosed via Renal Biopsy, and Response to Treatment. Journal of Nippon Medical School, 2010, 77, 348-351.	0.3	0
787	Pseudo-Obstruction of Jejunum due to AA Amyloidosis Associated with Latent Syphilis. Intestinal Research, 2010, 8, 195.	1.0	0

#	ARTICLE	IF	CITATIONS
789	A LONG-TERM REMISSION OF RENAL AMYLOIDOSIS WITH NEPHROTIC SYNDROME AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM-CELL TRANSPLANTATION. Fukushima Journal of Medical Sciences, 2010, 56, 151-156.	0.1	1
790	Renal Amyloidosis. , 2010, , 129-143.		1
792	Bortezomib in Systemic Light-Chain Amyloidosis. , 2011, , 135-148.		0
797	Atypical tumour-like involvement of the colon in secondary systemic amyloidosis which vanished after 1 month of observation. BMJ Case Reports, 2011, 2011, bcr0120113775-bcr0120113775.	0.2	0
798	Malabsorption. , 2011, , 9-20.		0
800	Bleeding Tendency of a Light Chain (AL) Amyloidosis Patient Accompanied by Asymptomatic Plasma Cell Myeloma. Laboratory Medicine Online, 2013, 3, 183.	0.0	0
802	Cardiac amyloidosis masquerading as biventricular hypertrophy in a patient with multiple myeloma. BMJ Case Reports, 2013, 2013, bcr2012008113-bcr2012008113.	0.2	0
803	A Rare Case of Chronic Diarrhea. Intestinal Research, 2014, 12, 78.	1.0	0
804	Dermatology in Kidney Disease. , 2014, , 525-536.		0
805	Anesthetic Management of a Patient with Severe Cardiac Amyloidosis Emergent Undergoing Upper Abdominal Surgery.. The Journal of Japan Society for Clinical Anesthesia, 1999, 19, 626-629.	0.0	0
806	Is the Catalytic Activity of Bence Jones Proteins an Autoimmune Effector Mechanism in Multiple Myeloma?. , 1999, , 235-247.		1
807	Multiple Myeloma and Other Plasma Cell Dyscrasias. , 1999, , 489-507.		0
808	Amyloidosis and the Respiratory Tract. , 2015, , 91-111.		0
809	Alterations of the Cerebrospinal Fluid in Chronic Inflammatory Diseases of the Peripheral Nervous System. , 2015, , 311-327.		0
814	Cardiac involvement Is Underdiagnosed in Patients with Biopsy-Proven Systemic AL Amyloidosis. International Cardiovascular Forum Journal, 0, 6, .	1.1	0
815	Cardiac amyloidosis: a case report. Intervencni A Akutni Kardiologie, 2016, 15, 145-147.	0.0	2
816	Two Cases of Systemic Amyloidosis with Macroglossia or Submandibular Swelling. Practica Otologica, 2017, 110, 815-821.	0.0	0
817	Myeloma-Associated Glomerular Disease. , 2017, , 1-15.		0

#	ARTICLE	IF	CITATIONS
818	AL amyloidosis that presented with marked hepatomegaly and polyclonal hypergammaglobulinemia. Tenri Medical Bulletin, 2017, 20, 63-72.	0.1	0
819	Severe Orthostatic Hypotension Complicating Multiple Myeloma. Journal of Onco-Nephrology, 2017, 1, e8-e12.	0.3	0
820	Two Cases of Systemic Amyloidosis with Macroglossia or Submandibular Swelling. Practica Otologica, Supplement, 2018, 152, 56-57.	0.0	0
821	Light Chain (AL) Amyloidosis and the Kidney. , 2018, , 1-10.		0
822	Right Atrial Deformation Analysis in Cardiac Amyloidosis - Results from the Three-Dimensional Speckle-Tracking Echocardiographic MAGYAR-Path Study. Arquivos Brasileiros De Cardiologia, 2018, 111, 384-391.	0.3	13
823	Portal Hypertension and a Stiff Liver. Cureus, 2018, 10, e2768.	0.2	0
824	A Recurrent Painless Waxy Nodule on the Nose. , 2019, , 363-368.		0
825	A Patient Presenting with Severe Hypoglycaemia and Autonomic Instability Found to Have Multiple Myeloma Complicated with Amyloidosis. European Oncology and Haematology, 2019, 15, 106.	0.0	0
826	Metabolic Disorders in the Liver. , 2019, , 151-171.		0
828	99mTechnetium-labeled cardiac scintigraphy for suspected amyloidosis: a review of current and future directions. Heart Failure Reviews, 2022, 27, 1493-1503.	1.7	3
829	Correlation between amyloid deposits affecting renal compartments and glomerular filtration rate during renal biopsy in a renal amyloidosis case series. Brazilian Journal of Medical and Biological Research, 2020, 53, e8625.	0.7	2
830	Budd-Chiari Syndrome: An Unusual Complication of AL amyloidosis. Turkish Journal of Haematology, 2020, 37, 130-131.	0.2	1
831	Monoclonal gammopathy of renal significance: clinical manifestation, pathogenic characteristic and treatment. Panminerva Medica, 2020, 62, 38-53.	0.2	0
832	Constrictive Pericarditis and Restrictive Cardiomyopathy. , 2008, , 311-327.		0
833	Amyloidosen. , 2007, , 528-535.		0
834	A first report of endoscopic ultrasound for the diagnosis of pancreatic amyloid deposition in immunoglobulin light chain (AL) amyloidosis (primary amyloidosis). JOP: Journal of the Pancreas, 2013, 14, 283-5.	1.5	6
835	Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Texas Heart Institute Journal, 2005, 32, 178-84.	0.1	73
836	Light chain cardiomyopathy. Structural analysis of the light chain tissue deposits. American Journal of Pathology, 1996, 148, 1397-406.	1.9	51

#	ARTICLE	IF	CITATIONS
837	Syncope from dynamic left ventricular outflow tract obstruction simulating hypertrophic cardiomyopathy in a patient with primary AL-type amyloid heart disease. <i>Texas Heart Institute Journal</i> , 2009, 36, 50-4.	0.1	10
838	Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. <i>American Journal of Blood Research</i> , 2012, 2, 9-17.	0.6	6
840	Chronic diarrhea as the initial clinical manifestation of light-chain amyloidosis with cardiac involvement despite negative duodenal and rectal biopsies. <i>Experimental and Clinical Cardiology</i> , 2013, 18, 148-50.	1.3	1
841	Isolated cardiac involvement in primary amyloidosis: presenting as sick sinus syndrome and heart failure. <i>Texas Heart Institute Journal</i> , 2013, 40, 615-8.	0.1	3
843	Prognostic value of high-sensitivity cardiac Troponin T in patients with endomyocardial-biopsy proven cardiac amyloidosis. <i>Journal of Geriatric Cardiology</i> , 2014, 11, 136-40.	0.2	13
844	Outcome of 121 patients with renal amyloid a amyloidosis. <i>Journal of Research in Medical Sciences</i> , 2014, 19, 644-9.	0.4	18
845	Evaluation of Syncope Reveals Cardiac Amyloidosis. <i>Kansas Journal of Medicine</i> , 2018, 11, 78-79.	0.1	1
846	Pulmonary amyloidosis: A case series. <i>Lung India</i> , 2019, 36, 229-232.	0.3	3
848	Non-variceal upper gastrointestinal bleed as first presentation of primary systemic amyloidosis - A case report. <i>International Journal of Health Sciences</i> , 2021, 15, 50-52.	0.4	0
849	Marked recovery of cardiac function by chemotherapy and autologous stem cell transplantation of a patient with heart failure with preserved ejection fraction due to primary amyloid light-chain amyloidosis: a case report. <i>European Heart Journal - Case Reports</i> , 2022, 6, ytac016.	0.3	0
851	Sequential Liver, Kidney, and Autologous Stem Cell Transplant for AL Amyloidosis: A Case Report. <i>Transplantation Proceedings</i> , 2022, 54, 197-201.	0.3	0
852	An Interesting Case of Proteinuria: AL Amyloidosis. , 0, 32, 73-76.		0
853	Focused review on nutritional status of patients with immunoglobulin light chain amyloidosis. <i>Current Problems in Cancer</i> , 2022, 46, 100833.	1.0	3
854	Gastric amyloidosis associated with multiple myeloma: A rare cause of upper gastrointestinal bleeding. <i>Advances in Digestive Medicine</i> , 0, , .	0.1	0
855	Liver Biopsy-confirmed Primary Hepatic Amyloidosis with Only Jaundice as the Initial Symptom: An Autopsy Case Report. <i>Internal Medicine</i> , 2022, , .	0.3	1
856	Cardiac Amyloidosis: A Case Report of Seven Patients. <i>World Journal of Cardiovascular Diseases</i> , 2022, 12, 160-167.	0.0	0
857	Neurological complications of multiple myeloma. , 2022, , 415-431.		0
858	Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist. <i>Internal and Emergency Medicine</i> , 2022, 17, 957-969.	1.0	6

#	ARTICLE	IF	CITATIONS
860	A Case of Systemic AL Amyloidosis Diagnosed by Screening Colonoscopy. Case Reports in Gastrointestinal Medicine, 2022, 2022, 1-5.	0.2	0
863	Pulmonary amyloidosis: A case series. Lung India, 2019, 36, 229.	0.3	6
864	The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement. Annals of Medicine, 2022, 54, 1226-1232.	1.5	3
865	Systemic Diseases. , 2016, , 739-804.		0
866	Multidisciplinary supportive care in systemic light chain amyloidosis. Blood Research, 2022, 57, 106-116.	0.5	5
869	Amiloidose pulmonar com apresentaÃ§Ã£o traqueobrÃªnquica: relato de caso clÃnico. , 2022, 101, .	0.0	0
870	Clinical Outcomes and Effectiveness of Heart Transplantation in Patients With Systemic Light-chain Cardiac Amyloidosis. Transplantation, 2022, 106, 2256-2262.	0.5	1
871	Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis. Frontiers in Oncology, 0, 12, .	1.3	4
872	Management of Renal Failure in Multiple Myeloma. , 0, , .		0
873	Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis. International Journal of Molecular Sciences, 2022, 23, 6336.	1.8	5
875	Identification of AL proteins from 10 Î»-AL amyloidosis patients by mass spectrometry extracted from abdominal fat and heart tissue. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 27-37.	1.4	4
876	Early Lymphocyte Recovery Predicts Superior Survival after Autologous Hematopoietic Stem Cell Transplantation for Patients with Primary Systemic Amyloidosis. Clinical Cancer Research, 2005, 11, 1210-1218.	3.2	46
877	Compromiso renal atÃpico en amiloidosis de cadena ligera. Revista Colombiana De NefrologÃa, 2022, 9, .	0.1	0
878	Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment. Journal of the National Comprehensive Cancer Network: JNCCN, 2023, 21, 83-90.	2.3	1
879	AN EXPERIENCE OF PRIMARY AMYLOIDOSIS FROM AN INDIAN TERTIARY CANCER INSTITUTE IN SOUTH INDIA. , 2022, , 61-63.		0
880	Gastrointestinal Symptoms. , 2023, , 107-118.		0
881	Amyloidosis and the Lungs and Airways. , 2023, , 77-93.		0
882	Echocardiographic phenotype for refined risk stratification and treatment selection in light chain amyloidosis with heart failure. Journal of Cancer Research and Clinical Oncology, 2023, 149, 8415-8427.	1.2	1